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1. ABSTRACT 
 
 
Prognosis in severe acute pancreatitis (SAP) 
 
 
Background. Acute pancreatitis (AP) is a common abdominal disorder with a severity 
varying from mild to fatal disease. Survival of patients with AP, and particularly in severe 
acute pancreatitis (SAP), is related to a combination of therapy-associated and patient-
related factors. Predicting an individual patient’s outcome remains problematic. There are 
only a few relevant methods for predicting mortality among patients with acute pancreatitis. 
The factors which cause death in most patients with SAP seem to be related specifically to 
the multiple organ dysfunction (MOD) syndrome. In the early phase of SAP multiple organ 
failure (MOF) seems to be caused by the same cytokine and inflammatory mediators as in 
septic shock. There are numerous ways to define and score MOD. There are three more 
recent scores: the MOD score, the Sequential (former Sepsis-related) Organ Failure 
Assessment (SOFA) score, and the Logistic Organ Dysfunction (LOD) score. These scores 
are designed to assess the severity and development of MOD as a single score. With an 
increasing number of patients surviving SAP more attention has been directed towards 
quality of life and long-term outcome, especially in patients with alcohol-induced disease. 
In studies with a small number of patients, quality of life and outcome after SAP have been 
good. However, only two of these studies have used generic multidimensional measures. 
Aims.  The first aim was to analyze a large consecutive series of patients with SAP to 
identify factors releted to the risk of dying during hospital treatment. Secondly, to construct 
a novel model to predic a fatal outcome in the early phase of SAP and to compare this 
model with current predictive models. Thirdly, to compare the MOD, SOFA, and LOD 
scores as predictors of hospital mortality, and to use one of these scores to assess the 
incidence and the prognostic usefulness of organ dysfunction/failure in patients with SAP 
treated in a general ICU. A further aim was to define the overall long-term post-discharge 
outcome after SAP. 
Patients and methods. The total number of episodes of AP in the study during the 10 years 
study period was 1539 of which 317 (21%) were SAP. A consecutive series of 270 patients 
with SAP was included to study the factors related to a fatal outcome by univariate and 
multivariate analyses.  
In addition, 234 patients with sufficient data were included to construct five logistic 
regression models and three artificial neural network (ANN) prognostic models to be 
applied on data from patients in the early phase of SAP. Two of these models were tested in 
an independent prospective validation set of 60 consecutive patients with SAP and 
compared with current predictive systems.  
113 consecutive patients with SAP treated in a general intensive care unit (ICU) were 
studied for assessment of MOD/MOF. Their clinical and laboratory data were collected 
during a period of 35 days. Their Acute Physiology and Chronic Health Evaluation 
(APACHE) II, MOD score, SOFA score and LOD score were calculated and compared with 
regard to hospital mortality. In addition, a daily maximum score and a total maximum score 
(the sum of the highest values for each organ dysfunction) were calculated for all three 
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scores. The area under the receiver operating characteristic curve (AUC) was used as a 
measure of the accuracy of the scores. 
Of the 283 patients with SAP, 211 survived. During follow-up for a mean period of 66 
months an additional 27 patients died. The Rand 36-item Health Survey with accessory 
questions was mailed to 174 eligible patients. The final study population comprised 145 
patients (the response rate was 83%). The study population was compared Finnish 
population scores matched for age and sex; accessory questions were analyzed separately. 
Main results By univariate survival analysis advanced age, a history of previous chronic 
medication, patient transfers from other hospitals, a high BMI, respiratory or renal failure, a 
need of pressor support and a need of abdominal surgery were factors that significantly 
predicted inpatient mortality. By multivariate stepwise logistic regression analysis, such 
factors were need of pressor support, renal failure requiring dialysis, advanced age, history of 
previous chronic medication and need of abdominal surgery. 
Out of five logistic regression and three artificial neural network models, the one prediction 
model considered optimal was a logistic model with four variables: age, highest serum 
creatinine value within 60 - 72 h of primary admission, need for mechanical ventilation, and 
chronic health status. In the validation set, the predictive accuracy, determined by the AUC-
value, was 0.86 for the chosen model, 0.85 for the ANN model using eight variables, 0.82 
for APACHE II, 0.78 for MOD score, 0.66 for Ranson, and 0.54 for Imrie scores. Among 
the patients treated in a general ICU accuracy was highest with daily maximum scores of 
AUC 0.85 for the SOFA score, 0.84 for the MOD score, and 0.84 for the LOD score. 
According to the maximum SOFA score, the highest mortality was associated with liver 
(83%, p<0.001) and renal (63%, p<0.001) failure. The mortality ratio in subgroup of 
patients who had failures of two organ system ranged from 50% to 91%. The highest 
mortality rate (91%) occurred among patients who had a combination of hepatic and renal 
failure. By multiple logistic regression analysis, only hepatic, renal, cardiovascular failure, 
and previous cardiovascular medication were independent risk factors for hospital mortality. 
There were no clinically significant differences regarding long-term HRQL between the 
study and the general population. Of the 145 patients 87% returned to work, 27% had 
recurrent pancreatitis, and 43% developed diabetes. Of the 113 patients with alcohol-
induced SAP 30% were abstinent and 28% were problem drinkers, alcohol-dependent, or 
alcoholics at follow-up. 
Conclusions. Previous chronic medication, advanced age, need of dialysis, mechanical 
ventilator support and pressor support are factors that independently predict the death of SAP 
patient. In SAP, Ranson and Imrie scores are inaccurate predictors of mortality. A novel 
predictive model based on four variables performs at least as well as the APACHE II system 
with 14 variables. In patients with SAP, organ dysfunction scores (MOD, SOFA, LOD) are 
accurate in comprasion with APACHE II for predicting death during hospital treatment. The 
maximum daily organ dysfunction scores were simple and useful for assessing MOD and for 
predicting hospital mortality of patients with SAP. Up to 13% of the SAP patients surviving 
initial hospitalization die within a few years. Among the survivors, long-term HRQL seems 
to be comparable to that of the general population, the majority returns to work and reduce 
their alcohol consumption markedly. The cost of treatment of SAP patients is high, but 
according to this study maximal treatment of these patients seems to be justified.  
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3. ABBREVIATIONS 
 
 
 
ANN  Artificial neural network 
ANN4  Artificial neural network model with 4 variables 
ANN5  Artificial neural network model with 5 variables 
ANN8  Artificial neural network model with 8 variables 
AP  Acute pancreatitis 
APACHE  Acute Physiology and Chronic Health Evaluation 
AUC  Area under receiver operating curve 
BMI  Body-mass index 
CI  Confidence interval 
CRP  C-reactive protein 
CT  Computed tomography 
ERCP  Endoscopic retrograde cholangiopancreaticography 
HRQL  Health-related quality of life  
IAP   Intra-abdominal pressure 
ICU  Intensive care unit 
IL  Interleukin 
LOD  Logistic organ dysfunction 
LR4  Logistic regression model with 4 variables 
LR5  Logistic regression model with 5 variables 
LR8  Logistic regression model with 8 variables 
MOD  Multiple organ dysfunction  
MOF  Multiple organ failure 
MRI  Magnetic resonance imaging   
OR  Odds ratio 
QOL  Quality of life 
RH  Relative hazard 
SAP  Severe acute pancreatitis 
SD  Standard deviation 
SE  Standard error  
SOFA  Sequential (former sepsis-related) Organ Failure Assessment 
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4. INTRODUCTION 
 
 
Acute pancreatitis (AP) is a common disease and its incidence is increasing (Thomson et 
al. 1987, Wilson and Imrie 1990, Jaakkola and Nordback 1993). AP is severe among 10–
30% of the patients. Biliary disease is the most common cause of AP in the United States, 
Asia and mos of Western Europe (Steinberg 1994). In contrast, up to 80% of the episodes 
of AP in Finland are alcohol-induced (Mero 1982, Puolakkainen et al. 1987, Jaakkola and 
Nordback 1993). The overall mortality rate among AP patients varies from 2% to 16%, and 
in severe acute pancreatitis (SAP) from 7% to 47% (Tenner et al. 1997). 
 
The factors which cause death in most patients with SAP seems to be related specifically to 
multiple organ dysfunction (MOD) syndrome. SAP-associated MOD resembles the MOD 
seen in other clinical settings such as sepsis, major trauma, and thermal injury (Miskovitz 
1998). In the early phase of SAP, multiple organ failure (MOF) seems to be caused by the 
same cytokine and inflammatory mediators as in septic shock, although pancreatic necrosis 
is sterile (Wilson et al 1998a). Early deaths caused by SAP are commonly associated with 
the MOD syndrome; these deaths account for 40 to 60% of in-hospital deaths in all age 
groups, and over the past decade this proportion has not declined (McKay et al 1999). 
 
Patients with SAP consume considerable health care resources, reguire prolonged hospital 
treatment, and the in-hospital mortality remains high. There is need for collaboration 
between many medical specialties, general practitioners, and social workers when SAP 
patients are treated, because these patients have a wide range of medical problems while 
being treated in the hospital and after being discharge, such as requirement of intensive 
care unit (ICU) treatment, infection problems, need of dialysis, surgical and radiological 
procedures, diabetes, symptoms of polyneuropathy, recurrent pancreatitis, continual 
abdominal pain, and often medico-social problems. 
 
The rising costs of ICU treatment and the ability to prolong the life of critically ill patients 
creates a need to identify early those patients who will benefit from intensive care and who 
will not (Atkinson et al. 1994). Several classification systems have been presented to assess 
the severity of AP. However, there are only a few practical methods for predicting if 
outcome in AP is fatal or not. Scores such as the Ranson (Ranson et al. 1974 and 1976, 
Ranson 1982), the Glasgow (Imrie et al. 1978a), the Blamey (Blamey 1984) and the Acute 
Physiology and Chronic Health Evaluation (APACHE) II scores (Knaus et al. 1985a) are 
practical for assessing the severity of the disease but they are not sufficiently well validated 
for predicting mortality. Survival in AP and particularly in SAP is related to therapy-
associated as well as patient-associated factors. Several isolated factors related to mortality 
in AP have been identified but there is currently no model to prognosticate a fatal outcome 
in SAP which would take all these single predictors into account. 
 
Much attention has been paid to quality of life and long-term outcome of patients surviving 
SAP, and especially to alcohol-induced SAP (Fenton-Lee and Imrie 1993, Orlando 3rd 
2000). Comments regarding the futility of treating patients with SAP, especially those with 
alcohol-induced SAP and MOF, are commonplace in clinical work.  
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In studies including only a small number of patients, the quality of life (QOL) and outcome 
after SAP have been shown to be good (Doepel et al. 1993, Fenton-Lee and Imrie 1993, 
Broome et al. 1996, Soran et al. 2000). However, only two studies on QOL assessment 
after SAP have used generic multidimensional measures (Broome et al. 1996, Soran et al. 
2000).  
 
The purpose of this study was to identify the prognostic factors related to hospital mortality 
and to construct a new model for predicting a fatal outcome of patients in the early phase of 
SAP. In addition, the aim was evaluate the clinical usefulness of assessing multiple organ 
failure associated with SAP in relation to hospital mortality. Furthermore, the aim was to 
define the overall long-term post-discharge outcome of patients after SAP. 
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5. REVIEW OF THE LITERATURE 
 
Moynihan described AP in 1925 in these words: “ It is the most terrible of all calamities that 
occur in connection with abdominal viscera. The suddenness of its onset, the illimitable 
agony which accompanies it, and the mortality attendant upon it, all render it most 
formidable of catastrophes.”  
 
The name of the pancreas (Greek: pan=all, kreas=flesh) was first recorded in about 100 
A.D. by Rufus of Ephesus, but the first description of this organ had been documented 400 
years earlier by Herophilus of Chalkaidon (Fitzgerald 1980).  
 
The pancreas secretes daily about 2500 ml isosmotic alkaline (pH > 8) fluid containing 
about 20 enzymes and zymogens. The pancreatic secretion contains the enzymes needed for 
the major digestive activities of the gastrointestinal tract and provides an optimum pH for 
the function of the digestive enzymes (Case 1998). The endocrine function of the pancreas 
is mediated by glucagon, insulin, and somatostatin. The endocrine cells mainly localized in 
the islets of Langerhans produce these hormones (Nauck 1998). 
 
AP is an acute inflammatory process of the pancreas that may involve the peripancreatic 
tissue and various remote organ systems (Bradley 1993). The final key mechanism 
operating in AP is related to autodigestion of tissues by the proteolytic enzymes of the 
pancreas itself. Evidence suggests that some cytokines [e.g., tumor necrosis factor- 
interleukin-1 (IL-1), IL-6 and IL-8], endotoxin and inflammatory mediators (e.g., platelet 
activating factor and phospholipase A2) are important in the development of the 
complications and MOF in SAP and sepsis (Wilson et al. 1998). 
 
The severity of AP is graded by the development of local complications and/or distant organ 
dysfunction. Common findings in SAP are abdominal pain, nausea, vomiting, paralytic 
ileus, fever, abdominal tenderness, abdominal distension, and tachycardia which are seen in 
65 to 95 % of patients. Less frequently patients have jaundice, tachypnea, respiratory 
insufficiency, hypovolemia, shock, pleural effusion, cardiac failure, renal failure, and 
abdominal mass (Z’graggen et al. 1998). 
 
 
5.1 Epidemiology of AP and SAP 
 
AP is a common disease in the developed countries and incidence is increasing (Svensson et 
al. 1979, Thomson et al 1987, Steinberg and Tenner 1994, Mckay et al. 1999). Pancreatitis 
is severe in 10–30% of the patients. In Finland, the incidence of AP has risen from 47/100 
000/year in 1970 to 73 in 1989, but the proportion of SAP did not increase in relation as 
much as did the incidence of mild AP (Jaakkola and Nordback 1993). In Scotland the 
incidence has increased from 26/100 000/year in 1985 to 42 in 1995 (McKay et al. 1999). In 
Finland 80% of AP the patients are male and the incidence of AP among males increased 
greatly between 1970 and 1989 (Jaakkola and Nordback 1993). A recent study from the 
Netherlands reports that the number of incidents has grown from 12/100000/year in 1985 to 
16 in 1995 and the incidence of AP has increased by 198% among males and 103% among 
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females from 1969 to 1995 (Eland et al. 2000). In children AP is usually associated with 
trauma (37% of cases); traumatic AP has been considered the most serious form of 
pancreatitis (Yeung et al. 1996). 
 
A nationwide survey in Finland showed that the incidence of AP among men grew 
markedly from 1984 to 1989 and that this was the case especially in the age group 25-44. 
This increase may be caused by the growing alcohol consumption in Finland (Jaakkola and 
Nordback 1993). However, in the Netherlands the number of incidents has grown while the 
total amount of alcohol consumed per inhabitant decreased during the study period. The 
increase in the incidence of AP in Netherlands was explained by the growing incidence of 
gallstone disease and of endoscopic procedures to the pancreatic and bile ducts (Eland et al. 
2000). Some of the change may be explained by improved diagnostic accuracy (Wilson and 
Imrie 1990). 
 
 
 
5.2 Pathogenesis of AP and SAP 
 
There are three classic theories to explain the pathogenesis of AP caused by gallstones: 
 
1) The flow/reflux theory chaims that there is reflux of duodenal contents into the pancreatic 
ductal system due a direct effect of the passage of a gallstone through the sphincter of Oddi 
or an effect of alcohol which reduces its tonus, relaxing the sphincter (McCutcheon 1968). 
2) According to the bile reflux theory an impacted gallstone obstructs the distal duct and 
creates a common channel between the bile and pancreatic ducts (Singh and Simsek 1990). 
3) The obstruction theory, states that the bile stones obstruct the pancreatic duct and with 
continued secretion there is hypertension in the pancreatic duct which causes extravasation 
of pancreatic fluid into the parenchyma (Steer 1992). 
 
Further theories include the toxic metabolic hypothesis which postulates that ethanol has a 
direct toxic effect on pancreas leading to AP, the trypsinogen activation hypothesis, the 
ischemia/reperfusion theory and the hereditary pancreatitis/gene mutation theory (Noronha 
et al.1981, Singh and Simsek 1990, Bettinger and Grendell 1991, Gullo et al. 1996, 
Whitcomb et al. 1996 a and b). 
 
There are many similarities between SAP, sepsis syndrome and septic shock. Evidence 
suggests that cytokines (tumor necrosis factor-  	
-1, interleukin-6, interleukin-8 
etc.), endotoxin and inflammatory mediators (platelet activating factor phospholipase A2 
etc.) are important in the development of complications and in the development of MOF, 
something that occurs in both SAP and sepsis (Wilson et al. 1998). 
 
Despite more than 100 years of experience and thousands of experimental, animal and 
clinical studies, the pathogenesis of AP and SAP is not well understood. Only a minority of 
patients with stones in the common bile duct or alcohol abusers gets AP. Perhaps the factors 
predisposing to SAP are multifactorial and explain our fragmentary understanding of the 
pathogenesis of SAP. 
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5.3 Etiology of SAP 
 
AP and SAP are probably caused by the same etiological factors. In this review of the 
literature all published etiological factors associated with SAP are discussed. Ethanol and 
gallstones cause 70-90% of the episodes of SAP. Endoscopic retrograde 
cholangiopancreaticography (ERCP), surgery and trauma are the next common causes. 
Other causes of SAP are rare.  
 
5.3.1 Ethanol and other toxins 
 
The association between alcohol abuse and pancreatitis was first described by Symmers 
(1917). According to Schenker and Montalvo (1998) the alcohol-related triggering 
mechanism or mechanisms leading to the autodigestion of pancreatic tissue have not been 
elucidated. The most persuasive concepts are the toxic-metabolic hypothesis, oxidative 
stress-induced specific production of free radicals and membrane lipid alteration (Schenker 
and Montalvo 1998). In addition, genetic factors may also play a role. Only 5% of alcohol 
abusers have clinical evidence of pancreatitis, but at autopsy changes consistent with 
chronic pancreatitis have been reported in up to 75% of the alcohol abusers (Singh and 
Simsek 1990, Schenker and Montalvo 1998). 
 
As far as other toxins are concered, methanol poisoning can cause a fatal form of SAP 
(Hantson and Mahieu, 2000), as may organophosphate poisoning (Panieri et al. 1997). 
 
5.3.2 Obstructive causes 
 
Opie (1901) was the first to describe the association between gallstones and pancreatitis. 
Gallstones are the most common obstructive cause of AP. According to the study of 
Steinberg and Tenner (1994), more women than men are affected, and the peak incidence 
age is between 50-60 years. In Finland gallstones are an etiological factor in only 10-20% of 
the attacks of AP, but when only females are considered, gallstones are the most common 
cause of AP (Mero 1982, Puolakkainen et al. 1987, Jaakkola and Nordback 1993) 
 
Rare causes of SAP have been reported related to ascariasis (Choi and Wang 1984), 
choledochal cysts (Goldberg et al. 1980), papilla Vater´s adenoma, papilla Vater´s 
carcinoma (Sato et al. 1999), pancreatic ductal adenocarcinoma (Zyromski et al. 2001), 
impacted papilla minor stone in pancreas divisum (Renzulli et al. 1999), pancreatic 
carcinoma (Mujica et al. 2000), and metastases (Gutman et al. 1993)  
 
5.3.3 ERCP, posttraumatic and iatrogenic causes  
 
Althougt the cause of AP is obvious in patients who have undergone ERCP, stent 
placement, or sphincterectomy, the mechanism indicing AP is not clear (Bank and Indaram 
1999). 1% to 3% of patients undergoing ERCP get fatal SAP (Fung et al. 1997). According 
to the study of Räty et al. (2001) 3 patients out of 315 (1 %) developed SAP as a 
complication of ERCP. Furthermore, the results suggested that the routine use of 
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prophylactic antimicrobial drugs reduces the incidence of AP following ERCP. Moreover, 
blunt or penetrating trauma to the pancreas can lead to an attack of SAP (Pollock 1959, 
Imrie et al. 1978b) 
 
Post-operative SAP may occur after many different surgical procedures. Most attacks of 
post-operative SAP are caused by abdominal surgery (White et al. 1970, Imrie et al. 1978b), 
transplantation surgery (Fernandez-Cruz et al. 1989, Camargo et al. 1995, Krokos et al. 
1995) or thoracic surgery (Adiseshiah et al. 1983, Fernandez-del Castillo et al. 1990, Lefor 
et al. 1992). Post-operative SAP is most likely induced by severe pancreatic ischemia 
leading to acinar cell injury (Gullo et al. 1996). Post-operative pancreatitis was found to be 
highly lethal (49% mortality) in a study involving 644 AP patients (Berman et al. 1961) 
 
Invasive medical procedures or treatments such as percutaneous biopsy of the pancreas 
(Mueller et al. 1988), manometry of the sphincter Oddi (Albert et al. 1988), extracorporeal 
shock wave lithotripsy of kidney stones (Abe et al. 2000), laser treatment of periampullary 
adenoma (Maunoury et al. 1993), peritoneal dialysis, and hemodialysis (Bruno et al. 2000) 
have also been associated with the development of SAP. 
 
5.3.4 Drugs and metabolic causes 
 
  		      	     
(1996) point out that the course of drug-induced AP is usually mild and self-limited. 
Nonetheless, SAP has anecdotally been reported to be associated with the use of nelfinavir 
(Di Martino et al. 1999) and meglumine antimoniate (Delgado et al. 1999) in HIV infection, 
with the use of propofol (Metkus et al.1996), enalapril (Gonzales Ramallo et al. 1992), and 
L-asparaginase (Garrington et al. 1998). 
  
Hypertriglyceridemia is associated with SAP (Toskes 1990, Ohmoto et al. 1999), whereas   
hyperparathyroid adenoma can cause hypercalcemia and this may in some cases lead to 
SAP (Shimizu and Kodama 1996). 
 
 
5.3.5 Infection and hereditary causes 
 
The following infections have been reported to cause SAP: hepatitis A (Davis and Keeffe 
1992), Coxsackie B4 (Kennedy et al. 1986), Coxsackie B5 (Gooby Toedt et al. 1996), 
parotitis virus (Feldstein et al. 1974), HIV (Parithivel et al.1999), and some parasites (Choi 
and Wong1984).  
 
Hereditary pancreatitis was described by Comfort in 1952 (Comfort 1952). It is a rare 
condition characterized by acute and chronic pancreatitis transmitted as an autosomal 
dominant trait in chromosome 7q35 (Whitcomb et al. 1996a and b, Sossenheimer et al. 
1997). In general, the attacks of hereditary AP are mild, but very seldom female have 
attacks of SAP during pregnancy and menstruation (Gates et al. 1999). 
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5.3.6 Other causes 
 
Pregnancy has been reported to be associasted with SAP; in most cases both biliary stones 
and biliary sludge are found in patients with AP in pregnancy and the postpartum period 
(Maringhini et al. 1993, Ramin et al. 1995, Maringhini et al. 2000). Necrotizing pancreatitis 
has also been reported in connection with polyarteritis nodosa (Flaherty and Bradley 1999), 
systemic amyloidosis in rheumatoid arthritis (Oishi et al. 2000) and primary sclerosing 
cholangitis (Goldin et al. 1990). 
 
5.3.7 Idiopathic SAP 
 
The cause of SAP cannot be established in from 2% to 40% of patients (Kemppainen et al. 
1996, Fernandez-del Castillo et al.1998, Gloor et al. 2001, Johnson et al. 2001, Buter et al. 
2002). 
 
 
5.4 Diagnosis of AP 
 
The diagnosis of AP and SAP is based on clinical, laboratory, radiological, surgical, and 
pathological findings. In the early 20th century, the diagnosis was only based on clinical, 
surgical and pathological findings (Moynihan 1925), but as laboratory methods developed, 
the importance of laboratory assessment has increased in diagnosis of AP. After 1985 
imaging procedures have established a central role in the diagnosis and classification of AP 
(Kivisaari et al. 1983 and Balthazar et al. 1985). 
 
Elman (1929) was the first to describe the association between elevated serum amylase 
activity and AP. The serum amylase activity has been the cornerstone in the diagnosis of 
AP. The serum amylase activity increases within hours of the onset of AP symptoms and is 
regularly normalized within 3-5 days. The normalization can sometimes occur very rapidly 
if the pancreatic tissue is extensively necrotic and may result in normoamylasemia already 
by the time the patient is admitted (Kemppainen et al. 1998a). Urine amylase activity 
increases later than the serum amylase. It has been shown that pancreatic amylase 
isoenzyme measurement (i.e, excluding the amylase activity from the salivary glands and 
other tissue) is more specific than total serum amylase measurement (Lin et al. 1989, 
Sternby et al. 1996). 
 
Lipase originates mainly from the pancreas. Consequently the serum lipase activity may be 
more specific and more sensitive than amylase levels for detecting AP (Ranson 1997). By 
using a cut-off level of serum lipase and amylase activities > 3 times normal, the diagnostic 
accuracy is improved for differentiating nonpancreatic abdominal pain from AP. The 
sensitivity of an enhanced amylase activity for diagnosing AP is 52-95% and the specificity 
is 86-98%, and for lipase 74-100% and 34-100%, respectively (Wong et al. 1993). These 
values are generally considered unsatisfactory. 
 
Trypsin is secreted from the pancreatic acinar cells as the proenzyme (zymogen) 
trypsinogen.  Trypsinogen is activated in the duodenum by enterokinase. Trypsinogen-1 and 
trypsinogen-2 are the two major isoenzymes and constitute 20 % of the pancreatic secretion 
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antitypsin) and their complexes can be measured by radioimmuno- and immunofluorometric 
assays. These assays have been reported to be useful for detecting AP, but none of them are 
used clinically (Itkonen et al. 1990, Hedström et al. 1994, 1996 b, c).  However, a rapid 
urinary trypsinogen-2 test strip has proven to be useful for the screening of AP (Hedström et 
al. 1996a, Kemppainen et al. 1997, Kylänpää-Bäck et al. 2000). 
 
5.5 Severity assessment of AP 
 
The first one to classify AP was Fitz in 1889. The classification suggested three types of 
disease: hemorrhagic, gangrenous and suppurative (Moynihan 1925). During the following 
decades the classification of SAP was based on categorizing patients on the basis of 
etiology. The first international attempt to classify and define pancreatitis, which was 
mainly based on morphological criteria, was made at the Marseille meeting in 1963 (Sarles 
1965). Three additional international attempts at classification were made. The first one in 
Cambridge 1983 (Sarner and Cotton 1984), the second one in Marseille 1984 (Singer et al. 
1985) and the third one in Marseille-Rome 1988 (Sarles et al. 1989). A new, clinically based 
classification system for AP and its complications were proposed in Atlanta in 1992 
(Bradley 1993). It adopted the following eight distinct clinical and morphological entities 
related to AP: mild and severe AP, interstitial edematous pancreatitis, sterile and infected 
necrotizing pancreatitis, fluid collections, pseudocyst and pancreatic abscess.  
 
5.5.1 Laboratory evaluation of SAP 
 
Amylase and lipase 
 
The levels of amylase or lipase do not correlate with the severity of AP, nor do they have 
any prognostic value. Therefore, they should not be used for the follow-up or for the 
severity classification of patients with AP (Nordback 1985a). 
 
Trypsin- based methods 
 
In assessment of the severity of AP the concentration of trypsinogen-2 (Hedström et 
al.1996b) and the trypsin-2-%1-antitrypsin complex (Hedström 1996c) have been reported to 
be useful. Trypsinogen activation peptide is released from trypsinogen when it is activated 
to trypsin during SAP (Formela et al. 1995). The measurement of trypsinogen activation 
peptide from plasma (Heath et al. 1994, Gudgeon et al. 1990) and urine samples 
(Neoptolemos et al. 2000) seems to be useful for staging AP. 
 
 
Inflammatory mediators 
 
C-reactive protein (CRP) is most widely documentated among the inflammatory mediators 
for the differentiation of severe and mild AP. The prognostic role of CRP in early AP is 
limited because of CRP values peak rather slowly; the delay may be 48 to 72 hours before 
peak levels are achieved. If peak CRP values, are over 150-120 mg/L 48 hours after 
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admission SAP is possible (Puolakkainen et al. 1987, Puolakkainen 1989, Isenmann et al. 
1993, Heath et al. 1995, Paajanen et al. 1995). 
 
The peak concentration of interleukin-6 (IL-6) occurs 24-48 hours before the rise of CRP 
values but otherwise the plasma profile increase parallels that of CRP. Interleukin-6 predicts 
SAP already at the time the patient is admitted (Leser et al. 1991, Viedma et al. 1992, Heath 
et al. 1993, Windsor et al. 1993, Inagiki et al. 1997, Ikei et al. 1998). Recently, many other 
proinflammatory cytokines (e.g., tumor necro & % '-1, IL-8, IL-18) and anti-
inflammatory cytokines (IL-10, IL-1Ra, IL-11, serum IL-2 Ra) have been reported to be 
markers for SAP (Norman et al. 1994, Pezzilli et al. 1994, Norman 1998, Chen et al. 1999, 
Hynninen et al. 1999, Osman and Jensen 1999, Hirota et al. 2000, Opal and Depalo 2000, 
Rau et al. 2001). 
 
The measurement of polymorphonuclear elastase and neopterin in serum as a marker of 
granulocyte activation has been used in the staging of AP (Gross et al. 1990, Domingues-
Munoz et al. 1991, Viedma et al. 1994, Schölmerich et al. 1996, Uomo et al. 1996b, 
Widdison and Cunningham 1996, Ikei et al 1998, Kaufman et al. 1998). 
 
Pancreatic phospolipase A2 has been suggested to play a key role in the pathogenesis of 
pancreatic tissue injury in AP. Group I phospolipase A2 clinical value in the diagnosis of 
AP. Group II phospolipase A2 is thought to play an important role in the development of the 
systemic inflammatory response and organ complications (Puolakkainen et al. 1987, 
Grönroos and Nevalainen 1992, Viedma et al. 1994, Grönroos et al. 1998, Hietaranta et al. 
1999, Nevalainen et al. 1999) 
 
Among the inflammatory mediators, only CRP is used in a clinical routine, but IL-6 and Il-
10 measurements and the trypsinogen dipstick test are also available commercially. 
 
It may be too optimistic to think that there is a single laboratory test to identify the attack of 
SAP. Instead, a combination of tests (testpanels) may be needed to predict SAP and the 
systemic complications of SAP (Windsor 2000). 
 
Others laboratory assessments 
 
In some studies pancreatitis-associated protein has shown to predict SAP (Kemppainen et 
al. 1998b), although controversial results have been reported (Pezzilli et al. 1997). 
Hepatocyte growth factor levels have also shown to be closely related to SAP (Ueda et al. 
1997). According to two recent studies the levels of endogenous plasma ascorbic acid are 
related to show SAP (Bonham et al. 1999, Abu-Zidan et al. 2000). The markers of oxidative 
stress (thiobarbituric acid reactive substances, myeloperoxidase, protein carbonyls and 
ascorbic acid) predict SAP (Abu-Zidan et al. 2000). Procalcitonin and granulocyte colony 
stimulating factor may also be useful for predicting SAP (Müller et al. 2000) as well is case 
for, amylin and serum amyloid A concentration (Phillips et al. 2000, Mayer et al. 2002). The 
level of procarboxypeptidase B in serum and urine has been shown to be valuable to 
detecting SAP (Appelros et al. 1998). 
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5.5.2 Clinical presentation 
 
SAP has usually a rapid onset. It is manifested by upper abdominal pain, vomiting, fever, 
tachycardia, leukocytosis, and elevated serum levels of pancreatic enzymes (Baron and 
Morgan 1999). 
 
The other clinical manifestations can be classified by the Atlanta classification or by 
subcutaneous manifestations. 
 
Atlanta classification: organ failures, hypovolemia, abdominal mass, pericardial effusion, 
cardiac tamponade, hematemesis, melena and hypocalcemia (Bradley 1993). 
 
Subcutaneous manifestations: Periumbilical lividity (Cullen’s sign) was described by Cullen 
in 1918 in association with a ruptured ectopic pregnancy and may present in SAP. Gray 
Turner’s sign described in 1919 in patients with SAP is defined periumbilical discoloration 
and discoloration in the flanks. Neither Cullen’s sign nor Grey Turner’s sign is specific for 
AP, since these signs are also seen in patients with perforated ulcer, liver disease, rupturated 
aortic aneurysm and ectopic pregnancy. Fox’s sign is defined as ecchymosis of the penis or 
below inguinal ligament and Walzel’s sign is livedo reticularis. Blauvert was first to 
describe subcutaneous fat necrosis in 1946 associated with AP. In patients with AP fat 
necrosis can be found in variety of extra-abdominal locations including the mediastinum, 
pericardium, myocardium, pleura, bone marrow, lower extremity joints, periarticular tissue, 
adrenal, and ovaries. (Cullen 1918, Grey Turner 1919, Blauvert 1946, Sigmund 1954, 
Scarpelli 1956, Jacobs et al. 1977, Wilson et al. 1983, Dickson and Imrie 1984, Francombe 
et al. 1995, Bem and Bradley 1998) 
 
SAP patients may have ascites, septicemia, duodenal obstruction, portal vein thrombosis, 
massive intra-abdominal hemorrhage, encephalopathy, and sudden blindness (Z’graggen et 
al. 1998). Most of these manifestations develop late in the course of SAP and may be rare 
(except for those in the Atlanta classification). The symptoms described above are related to 
SAP, but their prognostic value regarding mortality has not been evaluated. 
 
The clinical presentation in early SAP has only limited value. The sensitivity of the clinical 
presentation is poor, but the specificity seems to be good. SAP can be predicted correctly 
only in 34 to 39% of patients on admission by experienced clinicians (McMahon et al. 1980, 
Wilson et al. 1990). 
 
 
5.5.3 Imaging 
 
Plain abdominal and chest x-rays are important to identify pleural effusions, pneumonic 
infiltrations and abdominal emergencies. Pleural effusions are strongly associated with SAP 
(Lankisch et al. 1994, Maringhini et al. 1996, Heller et al. 1997). In the study carried out by 
Talamini et al. (1999) the serum creatinine concentration and chest radiography were useful 
for identifying, within 24 hours from admission, a group of SAP patients.  
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Sonography has only limited value in the diagnostics of SAP, since overlying bowel gas 
often obscures the pancreas. However, sonography is of more value in detecting or 
excluding gallstones and in the diagnosis and follow-up of established pancreatic fluid 
collections and abscesses (McKay et al. 1982). 
 
Dynamic contrast-enhanced CT is the diagnostic “golden standard” for objective 
verification of pancreatic necrosis (Kivisaari et al. 1983, Balthazar et al. 1985 and 1990, 
Block et al 1986). In necrotic areas the contrast density fails to exceed 30-50 Hounsfield 
units (normal range 50-150) after intravenous administration of contrast medium (Kivisaari 
et al. 1983, Balthazar et al. 1990). However, it should be remembered that identifying viable 
pancreas tissue on contrast-enhanced CT does not exclude SAP. In a recent study, 19% of 
the patients with necrotizing pancreatitis did not have pancreatic parenchymal necrosis on 
contrast-enhanced CT (Sakorafas et al. 1999). Intravenous contrast medium may be 
detrimental to the kidneys, but in a recent study performing a contrast-enhanced abdominal 
CT did not aggravate the severity of the disease in patients with SAP (Hwang et al. 2000). 
 
Kivisaari and Schröder developed a scoring system for extra-pancreatic findings, which 
correlated with the severity of AP (Kivisaari et al. 1983, Schröder et al. 1995). The extra- 
pancreatic findings included edema in part of the pancreas, edema of the entire pancreas, 
peritoneal fluid, perirenal fat edema, mesenteric fat edema, pleural effusion and bowel 
paralysis. Each of these findings scores one point. A total score < 4 suggests mild AP, and a 
score ( ) 	 *      +  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dysfuntion or failure when no intravenous contrast medium agents can be administered. 
 
Balthazar et al. (1985) published a scoring system based on the presence of pancreatic 
enlargement, peripancreatic edema, and fluid collections on computed tomography (CT). 
This system was further refined to include data on nonperfused and presumably necrotic 
pancreas in contrast-enhanced CT (Balthazar et al. 1990). The advantages of the Balthazar 
system are that it can be applied immediately and at any point during the patient’s 
hospitalization. In addition, it provides information about local complications. The CT-
based system has similar sensitivity and specificity rates as the APACHE II, Ranson and 
Glasgow systems have (Balthazar et al. 1990). 
 
 
At present, the routine use of CT scanning to differentiate between interstitial and 
necrotizing pancreatitis is controversial (Banks 1997). A recent study suggests that a 
contrast-enhanced CT on admission correlates significantly with the severity of the disease 
and cannot be replaced by conventional laboratory prognostic scores (Ranson/Imrie) 
(Lankisch et al. 2001). According to Kemppainen et al. (1996) early localization of necrosis 
by contrast-enhanced CT can predict the outcome in patients with SAP. In that study 
necrosis in the head of pancreas was associated with a poorer outcome than necrosis located 
in the tail of the pancreas. However, there are no randomized studies documenting an 
improved outcome when a CT scan is performed early in the course of an attack of AP. In 
the early phase of AP, an abdominal CT scan seems to be indicated if there are differential 
diagnostic problems (e.g., suspicion of intestinal perforation and pancreatic trauma) (Yousaf 
et al. 2003).  
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Contrast-enhanced magnetic resonance imaging (MRI) is an alternative primary imaging 
technique for detecting SAP in patients with AP. MRI and CT are concordant in 
distinguishing viable pancreatic tissue from areas of necrosis. MRI appears to be more 
precise than CT in characterizing the content of fluid collections and in demonstrating gall 
stones, although CT is better in detecting gas and calcifications (Piironen et al. 1997 and 
2000, Ward et al. 1997, Robinson and Sheridan 2000). 
 
Technetium-99m-hexametyl propylene amine oxine leukocyte scintigraphy may be useful in 
identifying SAP patients from other AP patients (Schölmerich et al. 1991, Papos et al. 1997, 
Werner et al. 1998). However, this method has not achieved widespread use. 
 
Vesentini and coworkers introduced a system based on the extent of pancreatic necrosis in 
CT alone and reported a good correlation with clinical outcome (Vesentini et al. 1993).  
 
 
5.5.4 Scoring systems 
 
Ranson and Glasgow 
 
Ranson et al. (1974) developed the first scoring system for all AP patients and later for 
patients with gallstone pancreatitis (Ranson 1982). The Ranson criteria have an estimated 
sensitivity of 72% and specificity of 76%. Their positive predictive value is around 51% and 
the negative predicting value 89% (Steinberg 1990). 
 
The Glasgow criteria were developed in the late 1970s (Imrie et al. 1978a). Since then the 
criteria have been modified three times (Osborne et al. 1981, Blamey et al. 1984, Corfield et 
al 1985). The Glasgow criteria have an estimated sensitivity of 63%, a specificity of 84%, a 
positive predictive value of 52%, and a negative predictive value of 89% (Steinberg 1990). 
 
Both criteria include clinical and laboratory variables during the initial 48 hours of 
admission and thus the differentions between severe or mild AP is made at this time point. 
These criteria are not valid for repeated measurements beyond 48 hours. 
 
Atlanta classification 
 
According to the Atlanta classification SAP is associated with systemic and local 
complications (Bradley 1993).   
 
The systemic complications are: 
  
• organ failure [shock (systolic blood pressure < 90 mm Hg), pulmonary failure (PaO2 
, -.  /$  &	  + 0 !11 23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gastrointestinal bleeding (>500 ml/24 hours)]  
• systemic fibrionolysis [disseminated intravascular coagulation (platelets , !.. ...3
mm
3
, fibrin split products > 80µg/mL)] and severe metabolic disturbance (serum 
calcium level , !#1 3$  
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The local complications are: 
  
• pancreatic necrosis (an area of more than 3 cm diameter or involving more than 30 
% of pancreas in CT and contrast density increase < 50 Hounsfield units in the area 
of necrosis after intravenous administration of contrast medium. In addition, 
pancreatic necrosis or peripancreatic necrosis defined at surgery characterize SAP)  
• acute fluid collections (occur early in the course of AP, and are located in or near the 
pancreas, and always lack a wall of granulation or fibrous tissue) 
• abscess (a circumscribed intra-abdominal collection of pus, usually in proximity to 
the pancreas, containing little or no pancreatic necrosis, which arises as a 
consequence of AP or pancreatic trauma) 
• pseudocyst (a collection of pancreatic fluid enclosed by a wall of fibrous or 
granulation tissue, which arises as a consequence of AP, pancreatic trauma, or 
chronic pancreatitis)  
 
The Atlanta classification for SAP is broad since it includes also patients whose risk of 
death is not high (e.g., patients developing uncomplicated necrosis, pseudocyst or abscess). 
It is also retrospective (e.g., the development of a pseudocyst takes over 4 weeks). In the 
literature the definitions of SAP have been confusing before the Atlanta classification but 
also after it. For example, when predicting the outcome of a patient with SAP, some studies 
use the Atlanta classification of SAP whereas other studies include only a part of their SAP 
patients for assessment of prognosis (e.g., patients with pancreatic necrosis, infected 
necrosis, and organ or multiple organ failure). 
 
APACHE II  
 
APACHE II was developed as a general measure for ICU patients to estimate the severity of 
a disease, but it was quickly recognized for its potential for staging of patients with AP 
(Knaus et al. 1985a, Larvin and McMahon 1989, Wilson et al. 1990). Unlike the Ranson 
and Imrie criteria, the APACHE II system is a valid method for the prediction of the 
severity of AP on admission. The APACHE II system have comparable sensitivity and 
specificity rates to the Ranson and the Imrie criteria. The APACHE II system with its 14 
variables and 96 alternatives is more complicated and cumbersome than the Ranson and the 
Imrie criteria. APACHE II and the Simplified Acute Physiology Score (SAPS) systems are 
of limited clinical utility in the early prognostic evaluation of AP (Domínguez-4	5  
1993). However, according to Khan et al. (2002) a deterioring APACHE II score at 48 hours 
after admission may identify patients who have a poor outcome. 
 
Artificial neural network 
 
Artificial neural networks (ANN) have been used to predict the duration of hospital stays in 
AP (Pofahl et al. 1998). ANNs have been successfully used for pattern recognition and 
survival prediction in several clinical settings (Dybowski et al. 1996, Golub et al. 1998, 
Lundin et al. 1999). ANNs offer a way of capturing nonlinearities and complex interactions 
between prognostic factors in a multivariable model (Burke 1996).  
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Other scoring systems 
 
Diagnostic peritoneal lavage was successful in 95% of the AP patients who had free 
peritoneal fluid and the lavage fluid was useful for prediction of SAP (McMahon et al. 
1980). However, lavaging is invasive and it cannot be justifieably carried out in all patients 
with AP. Bank et al. (1983) have also described an criteria for prediction of SAP. Fan et al. 
(1989) found that serum urea (>7.4 mmol/L) and plasma glucose (>11.0 mmol/L) on 
admission predicted SAP and that the predictive powers of these assessments were 
comparable with the Glasgow multifactor scoring system (Hong Kong criteria). Obesity 
may predispose to SAP (Suazo-Baráhona et al. 1998). The risk of SAP in AP patients is 
increased if the patients has an age greater than 55 years, male sex, AP of unknown origin 
or alcohol-related (Pezzilli et al. 1998). A high hematocrit (())6$    
failure of the hematocrit to fall during the first 24 hours in hospital was the best binary 
predictors of necrotizing pancreatitis according a study by Brown et al. (2000). None of 
these systems are widely used.  
 
 
5.6 Treatment of SAP 
 
In most Finnish hospitals most patients with AP – whether of the mild or severe form – are 
treated in surgical wards or ICUs. The Department of Gastroenterological and General 
Surgery, at Meilahti hospital, has a long tradition of research and treatment of AP in Finland 
(Kivilaakso et al. 1984, Puolakkainen et al. 1987, Kemppainen et al. 1997, Sainio et 
al.1997), and serves as a tertiary referral center for a population of about 1.3 million 
inhabitants. The basic principles of treatment of AP have remained the same during the 
study period. Adequate initial resuscitation (fluid replacement up to 10 liters or more on the 
first day of treatment) is followed by aggressive nonoperative management with invasive 
monitoring and organ system support in an ICU, including treatment with early antibiotics 
for infection prophylaxis and prophylaxis for stress ulcers and thromboembolism. 
Necrosectomy is performed usually at the end of the third to fourth week in patients who 
have infected peripancreatic necrosis and worsening MOD (Leppäniemi 2003 and Uhl et al. 
2003). 
 
5.6.1 Conservative treatment 
 
The conservative management of SAP is based on the two-phased nature of the disease. The 
first phase can continue for 14 days and is characterized by a systemic inflammatory 
response syndrome maintained by the release of various inflammatory mediators. As a 
result of this inflammatory mediators may lead to single or multiorgan failure (Norman et 
al. 1998, Gloor et al. 2001a). Surgery during the first phase of SAP does not seem to be 
appropriate (Büchler et al. 2000). The second phase is dominated by infectious sepsis 
related complications. During the second phase infection of pancreatic necrosis may occur. 
 
General ICU management 
 
The principles of ICU management in SAP include treatment of secondary causes of organ 
failure, such as hypovolemia, hypoxemia and tissue hypoperfusion. To achieve this, 
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adequate monitoring (e.g., arterial catheterization, pulmonary arteria catheterization for 
measuring pulmonary capillary wedge pressure, central venous catheterization for 
measuring central venous pressure) and aggressive support of ventilation and the 
cardiovascular system are necessary. 
 
Rapid intravenous fluid therapy to correct dehydration is crucial for successful resuscitation 
of patients with SAP. In the early phase of SAP, the need of colloid and crystalloid fluid can 
be very high [1-3 L/hour and up to 10 L/day or more for normal weight (70 kg) patient]. 
Meta-analyses suggest that the use of human albumin to patients with a critical illness may 
increase mortality, and thus human albumin is not recommended (The albumin reviewers 
2001). Fluid resuscitation can be considered successful if a pulmonary capillary wedge 
pressure of 12-16 mmHg or a central venous pressure of 8-12 mg is achieved.  
 
If fluid resuscitation is not sufficient to achieve the targets (mean arterial pressure >65 or 
more), the use of one drug or combining vasoactive drugs [dopamine (2-10µg/kg/min), 
doputamine (2-10µg/kg/min), dopexamine, norepinephrine (0.05-3.0 µg/kg/min) or 
epinephrine] are needed. With the help of pulmonary capillary wedge pressure 
measurements, we can achieve the lowest loading stage of cardiac stroke volume and 
cardiac volume to ensure sufficient tissue oxygen import and transport. The target is to 
achieve at least mean arterial pressure of at least 65 mmHg and mixed venous oxygen 
saturation of 65% (Pettilä 2002). 
 
Insufficient ventilation is initially diagnosed on the basis of blood-gas analyses, ventilation 
frequency, and oxygen saturation. Treatment consists of supplemental oxygen through an 
oxygen mask, CPAP (continuous positive air pressure) or mechanical ventilation. The 
markers of tissue oxygen hypoxia consist of low mixed venous oxygen concentration, high 
lactate concentration and metabolic acidosis (Pettilä 2002). 
 
If acute renal failure develops in spite of rapid intravenous fluid therapy, continuous 
replacement of renal function should be started without delay to ensure optimal fluid and 
metabolic control and to ensure unlimited nutritional support without hemodynamic 
instability. Early hemodiafiltration has been shown to be more effective than late 
hemodiafiltration in patients with sepsis (Bellome and Ronco 1999). Continuous veno-
venous hemofiltration tends to cause less hemodynamic instability than intermittent 
hemodialysis (Forni and Hilton 1997).  
 
Increased intra-abdominal pressure (IAP), which may lead to the abdominal compartment 
syndrome is a known complication of SAP (Gecelter et al. 2002). A high IAP is manifested 
clinically by increased airway pressures, decreased cardiac output, oliguria, decreased 
visceral perfusion and increased cerebrospinal pressure and may lead to MOF (Gecelter et 
al. 2002). The IAP may be estimated by a validiated bladder measurement technique as is 
nowadays done at Meilahti hospital with ICU treated SAP patients (Fusco et al. 2001). In 
patients with a high IAP and the abdominal compartment syndrome decompressive 
laparotomy may be considered (Gecelter et al. 2002). However, the value of a 
decompressing lapartomy will have to be investigated by a randomized controlled trial 
before any general recommendations can be made (Sugrue 2002, Z’graggen and Gloor 
2002). 
  
26 
26 
 
Sufficient analgesics are mandatory to reduce the metabolic stress and to reduce the 
patients’ discomfort. Conventionally SAP patients treated in ICU´s consist of high doses of 
opioids, often combined with sedatives. A German study has shown that epidural anesthesia 
provides good pain relief and can be safely used in patients with SAP (Niesel at al. 1991). 
The main advantage of epidural analgesia in patients with SAP is that side effects of high 
doses sedatives can be avoided, and usually patients are more awake, and are frequently 
able to breathe spontaneously (Sigurdsson 1998).  
 
Patients who are treated in ICU and have a hemoglobin level of 70-90 g/L have a similar 
prognosis as patients with levels over 100g/L (Hebert et al. 1999). Thus low hemoglobin 
values should be appropiately considered when blood transfusions are planned for patients 
with SAP.  
 
Intensive insulin therapy to maintain blood glucose between 4 to 6 mmol/l may reduce 
morbidity and mortality among critically ill patients (Van den Berghe et al. 2001), and thus 
optimal glucose control should also be considered for patients with SAP. 
 
Infection prophylaxis 
 
Bacterial translocation from the gut is the main cause of secondary infection of necrotic 
pancreatic tissue (Runkel et al. 1991, Widdison et al. 1994, Moody et al. 1995). 
Percutaneous sonographical or CT-guided aspiration samples for bacteriological studies are 
the cornerstone of identification of infected pancreatic necrosis in patients with SAP 
(Gerzof et al. 1987, Paye et al. 1998, Rau et al. 1998). 
 
In two controlled and uncontrolled studies using selective gut decontamination (oral and 
rectal norfloxacin, colistin and amphotericin: and intravenous cefotaxime 500 mg every 8 
hours) lower mortality, lower gram-negative pancreatic infection, and lower gram-negative 
intestinal colonization was achieved (Luiten et al. 1995, 1998). In a prospective randomized 
trial study carried out by Sainio et al. (1995) lower mortality and fewer infectious 
complications was achieved among patients with alcohol-induced necrotizing pancreatitis 
by using intravenous cefuroxime versus patients who received no antibiotic. In two studies 
in which intravenous imipenem was used the results indicated a lower incidence of 
pancreatic necrosis infection and a trend toward reduced mortality was achieved (Pederzolli 
et al. 1993, Ho et al. 1997). Decreased pancreatic and extrapancreatic infection rates were 
found in a randomized study by using imipenem comparing to pefloxacin, though mortality 
was similar (Bassi et al. 1998). However, all of these studies were underpowered and their 
results do not allow any definitive conclusion to be made. 
 
A recent meta-analysis suggested that the use of prophylactic antibiotic reduces sepsis and 
mortality in patients with acute necrotizing pancreatitis (Sharma and Howen 2001). 
Prophylactic antibiotic administration seems to be beneficial, and as a result of this 
significant body of evidence, clinicians in charge with treating AP in the United Kingdom 
and Ireland now use antibiotic prophylaxis in the initial treatment of patients with a risk of 
SAP (Powell et al. 1999). 
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The need for surgery in patients with SAP is reduced if prophylactic antibiotic therapy 
(imipenem-cilastin) is started early rather than on-demand (Nordback et al. 2001). Räty et 
al. (1998) pointed out that in patients with alcohol-induced SAP gram-positive bacteria were 
found more often in infected pancreatic necrosis, and in patients with biliary SAP Gram-
negative bacteria were more common. 
 
Gram-negative rods are the main cause for early pancreatic necrosis infection. In a recent 
study (Büchler et al. 2000), the use of early antibiotic (imipenem/cilastin) changed 
pancreatic infection to predominantly gram-positive and fungal infections and the time 
when infection occurred was later than in earlier studies (Beger et al. 1986a and 1989, 
Büchler et al. 1992, Pederzoli et al 1993, Luiten et al. 1995, Sainio et al. 1995).  
 
Fungal intra-abdominal infections in patients with SAP may complicate the disease and 
increas mortality (Hoerauf et al. 1998, Grewe et al. 1999). Early fungicide antibiotics should 
be considered for patients with SAP who are treated in an ICU (Gloor et al. 2001b). 
 
Nutritional management 
 
Traditionally, patients with SAP were treated with total parenteral feeding because enteral 
feeding was thought to stimulate the pancreas and worsen pancreatic injury (Feller et al. 
1974, Kalfarentzos et al. 1991). On the contrary, recent data suggest that enteral feeding is 
actually well tolerated and does not affect recovery of the pancreas. Some prospective 
studies suggest that early enteral nutrition may result in fewer total and septic 
complications, and enteral nutrition may, in fact, significantly improve the acute phase 
responses and the severity scores of the disease. If this is case generally, costs will be 
reduced as patients may not need parenterial nutrition as much as has been customary. 
(Kalfarentzos et al. 1997, McClave et al.1997, de Beux et al. 1998, Windsor et al.1998). 
 
A randomized controlled study (Sax et al. 1987) showed that there is no added advantage of 
using parenteral nutrition vs no nutritional support, and another study concluded that there is 
no evidence of an improved outcome SAP patients who have received early enteral nutrition 
vs parenterial nutrition (Powell et al. 2000).  
 
Clearly, larger, well conducted trials that include only patients with SAP and that stratify 
patients by disease severity, nutritional status and etiology of pancreatitis before 
randomization are needed before any clear position on the benefits of nutritional support on 
outcome can be taken (Lobo et al. 2000). Enteral feeding through a nasojejunal (Windsor et 
al.1998) or nasogastric (Eatock et al. 2000) tube is current practise used at Meilahti hospital 
in the treatment of patients with SAP. 
 
Specific medical treatment 
 
Besides antibiotics, no single pharmacological therapy has proven to be effective with 
regard to the outcome of SAP or MOF. Many drugs have been tried, but the vast majority of 
these studies are inadequately powered to assess mortality. 
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Two prospective case-control studies suggested a beneficial effect of octreotide in patients 
with SAP (Fiedler et al. 1996, Paran et al. 2000), but the majority of trials showed no 
benefit at all (Planas et al. 1998, Uhl et al. 1999).  The use of somatostatin or its analogues 
has been reported to be useful in preventing the formation of pseudocysts (Büchler et al. 
1994). In a study conducted by Leese et al. (1987) low volumes of fresh frozen plasma were 
used in the treatment of AP, but this did not translate into a statistical difference in 
mortality.  
 
Glucagon, calcitonin, fluorouracil, and atropin have also been in controlled studies in an 
attempt to reduce mortality, but these drugs have not affected mortality (Cameron et al. 
1979, Goebell et al 1979, Kronborg et al. 1980, Saario 1983). 
 
According to Büchler et al. (1993) gabexate mesilate was not effective in preventing 
complications and mortality in AP. However, a recent study showed that early intravenous 
gabexate mesilate infusion resulted in improved survival in SAP patients with organ 
dysfunctions (Chen et al. 2000). 
 
Platelet-activating factor antagonist (Lexipafant®) reduces organ dysfunction according to a 
phase II trial, but the results from a phase III multicenter trial were disappointing: there was 
no reduction in the incidence of organ failure in patients on lexipafant treatment.  It  seems 
that the antagonism of platelet-activating factor activity does not influence the course of 
organ failure in SAP (Kingsnorth et al. 1995, Mckay et al. 1997, Johnson et al. 2001). 
 
5.6.2 Operative options 
 
Indications of surgery 
 
In the early 20th century early surgical intervention to treat SAP was widely regarded as 
unnecessary and conservative management was favored (Moynihan 1925, Paxton and Payne 
1948). In the mid-20th century Pollock (1959) and Trapnel (1966) began to reassess the role 
of surgery in patients with SAP. In 1963, Watts started a period of aggressive surgical 
treatment and this approach became widely accepted in a number of European countries. 
After the mid-1980´s aggressive surgery for all SAP patients was found to be unnecessary 
(Beger et al.1985) and only some subgroups of patients with SAP should be operated on by 
late necrosectomy (Beger et al. 1986a, Mier et al. 1997). Currently only infected 
peripancreatic necrosis is a generally accepted indication for operation (Büchler and Reber 
1999, Uhl et al. 2003, Yousaf and al. 2003). 
 
Pancreatic resection and pancreatectomy 
 
Excision of the irreversibly damaged part of pancreas or total pacreatectomy was suggested 
as the appropriate treatment in some studies from 1960 to 1985 (Watts 1963, Kyösola and 
Fock 1975, Alexandre and Guerrieri 1981, Kivilaakso et al. 1981 and 1984, Aldridge et al. 
1985). However, since pancreatic resection causes many complications and does not affect 
organ failures beneficially (Nordback et al. 1986, Teerenhovi et al. 1988), it should be 
avoided.  
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Peritoneal lavation 
 
Peritoneal lavage was suggested as a treatment of SAP in some studies (Wall 1965, Stone 
and Fabian 1980, Ranson and Berman 1990). In a controlled clinical study conducted by 
Mayer et al. (1985) peritoneal lavage did not carry any advantage over conservative 
treatment. 
 
Debridement, necrosectomy and drainage 
 
Penrose/sump drainage was first reported as surgical treatment of SAP in 1963 (Altemeier 
and Alexander). This method had a mortality rate between 3% and 82% (Allardyce 1987, 
Wilson et al. 1988b, Howard 1989). 
 
Careful, late-phase finger necrosectomy via a midline, subcostal or transverse abdominal 
incision is the basic surgical approach to manage patients with SAP. Here, multiple drainage 
tubes are placed intraperitoneally and post-operative lavage should be considered (Beger et 
al 1988, Beger and Isenmann 1999). 
 
Necrosectomy and open packing as well as planned re-operation has been used in some 
centers in the USA as a surgical treatment of SAP (Bradley 1987, Bradley and Allen 1991, 
Margulies and Akin 1996, Bosscha et al. 1998). Necrosectomy and closed packing with or 
without a zipper technique, and planned reoperation is a method of surgical treatment in 
other centers (Branum et al. 1998, Tsiotos 1998). 
 
Debridement and closed packing via laparotomy with penrose or Mikulicz drains and closed 
suction drains is an alternative choice for surgical treatment of SAP (Fernandez-del Castillo 
et al. 1998, Paye et al. 1999). Some centers use the retroperitoneal approach to operate on 
necrosis (Fagniez et al. 1989, Villazón et al.1991). Debridement can also be done 
endoscopically through a short lumbotomy (Gambiez et al. 1998) or laparoscopically 
(Alverdy et al. 2000, Hamad and Broderick 2000). 
 
ERCP 
 
In suspected biliary SAP ERCP within 72 hours and, if present, extraction of common bile 
duct stones should be considered. In patients with icterus or cholangitis, the extraction of 
stones is a necessity (Neoptolemos et al 1988, Fan et al. 1993, Fölsch et al 1997). 
 
An intrapancreatic nasopancreatic lavage catheter and double pigtail catheters may be 
placed endoscopically to treat organized pancreatic necrosis (Baron et al. 1996, Baron et al. 
1999b). However, infection can occur after endoscopic decompression of pseudocysts, if the 
pancreatic necrosis in the pseudocysts is unrecognized (Hariri et al.1994). Disruption of the 
main pancreatic duct by ERCP was observed in 31% of the cases in patients with biliary 
SAP. Moreover, disruption of the main pancreatic duct was not generally an absolute 
indication of surgery in patients with sterile necrosis (Uomo et al. 1998) 
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Interventional radiology 
 
Percutaneous CT-guided insertation for drainage is one way to treat infected necrosis 
(Echenique et al. 1998, Freeny et al. 1998). There is, however, a risk of persistent 
pancreaticocutaneous fistula after percutaneous drainage of pancreatic fluid collections  
(Fotoohl et al. 1999). Percutaneous necrosectomy can also be done laparoscopically under 
CT-guidance (Douzinas et al. 1997, Carter et al.2000).  
 
5.6.3 Future treatment options 
 
A vascular access system for arterial infusion of a protease inhibitor and antibiotics in 
patients with SAP has been developed with promising results (Anai et al. 1999, Ganaha et 
al. 1999). The use of the physiological anticoagulants antitrombin III and activated protein 
C reduces mortality in patients with sepsis (Eisele et al. 1998, Bernard 2001), but no trial 
among patients with SAP has been reported with these drugs. There is some preliminary 
information on using extracorporeal membrane oxygenation for acute respiratory failure 
secondary to SAP (Peek et al. 1998). 
 
5.7 Prognostic factors for fatal outcome in SAP 
 
Among patients with AP each factor that predicts SAP is also a predictor of death, because 
mortality in mild AP is very low and mortality in SAP is 10 to 30 times higher. Thus, when 
studies which search for the prognostic factor in AP are avaluated, it must be kept in mind 
that a prognostic factor among all patients with AP may not be a prognostic factor for death 
among patients with SAP. 
 
5.7.1 Prognostic factors on admission 
 
Advanced age is a negative prognostic indicator in AP (Ranson and Pasternack 1977, 
Blamey et al. 1984, Williamson 1984, Roumen et al. 1992), but this has not been the case in 
all reports (Fan et al.1988, Lankisch et al.1996) 
 
Several studies have identified a number of outcomes depending on the underlying etiologic 
factors related to AP (Imrie 1974, Ranson et al. 1976, Frey 1981). However, the cause of the 
AP was not associated with mortality in a report of 190 patients (Uhl W et al. 1996). 
 
The influence of admission-related factors was evaluated in a study of DeBeux and 
coworkes (1995) with 279 patients with AP. The mortality rate was 2% among those 
patients who were directly admitted to the study hospital, but it was 10-fold higher for 
patients referred from another hospital. 
 
Diabetic patients have an increased risk dying of AP compared to non-diabetic patients 
(Renner et al. 1985). 
 
According to Enquist et al. (1958), the incidence of obesity among the patients with 
pancreatitis who died was much higher than the incidence of obesity among control patients. 
In another study obesity was associated with extensive peripancreatic and septal necrosis 
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(Nordback et al. 1985b). The role of obesity has been pointed out as a prognostic factor for 
AP (Lankisch et al.1990. Porter and Banks 1991, Funnell et al. 1993, Martínez et al. 1999). 
However, the mortality rate was not higher for obese patients among 320 patients with AP, 
but obese patients did have a higher risk of local complications in the course of AP (Tsai 
1998).  
 
5.7.2 Laboratory tests 
 
Only few laboratory tests predict of a fatal outcome in SAP. In a recent study, a high 
hematocrit (())6$    &	 &   ocrit to decrease during 
24 hours were the best binary predictors of necrotizing pancreatitis and organ failure 
(Brown et al. 2000). Hypocalcemia predisposes to death among SAP patient (Shader et. al. 
1966). 
 
5.7.3 Organ failure and multiple organ dysfunction/failure 
 
Single and multiple organ failure have been identified as prognostic factors related to a fatal 
outcome of patients with AP and SAP (Allardyce et al. 1987, Lumsden and Bradley 1990, 
McFadden 1991, Karimgani et al. 1992, De Beaux et al. 1995 and 1996, Uomo et al. 1996a, 
Tenner et al. 1997).  
 
Fulminant hepatic failure and chronic liver disease increase mortality in patients with AP 
(Kuo et al. 1998). In a study of 267 patients with AP the mortality rate of patients with acute 
renal failure was 81%, and in another study with 14 patients the mortality rate was 71% 
(Frost et al. 1990, Tran et al. 1993b).  
 
On admission 30% of patients with SAP had organ failure and their mortality rate was 42% 
(Isenmann et al. 2001). In another study 44% of the patients with SAP had organ failure on 
admission and, contrariwise, 97% of the patients who died had organ failure within the first 
week of admission (Johnson et al. 2001). In a recent study by Buter et al. (2002) it was 
shown that worsening of organ dysfunction during the first week of admission was 
associated with death in 11 patients of 20 (55%) with SAP. 
 
5.7.4 Infection 
 
Infected pancreatic necrosis develops in 40-70% of the patients with necrotizing pancreatitis 
(Schmid et al. 1999). Beger et al. (1986b) reported a postoperative mortality rate of 39% in 
patients with peripancreatic necrosis and bacteriological positive findings, whereas the 
mortality rate was 9% in bacteriologially negative patients. Bacterial infection of pancreatic 
necrosis correlates with the incidence of organ failure in patients with SAP (Isenmann et al. 
1999). In a study by Armengol-Carrasco et al. (1999) the CRP levels and the APACHE II 
score were related to the development of peripancreatic necrosis infection in patients with 
SAP. 
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5.7.5 Scoring systems 
 
Ranson and Glasgow 
 
The Ranson and Glasgow scores have been developed for predicting the severity of acute 
pancreatitis, but they have also been used for predicting fatal outcome (Ranson et al. 1974, 
and 1976, Corfield et al. 1985). However, a recent meta-analysis demonstrated that the 
Ranson criteria have a poor predictive power for a fatal outcome in SAP (De Bernardinis et 
al. 1999). In contrast, a recent study by Eachempati et al. (2002) found the Ranson score 
was a valid predictor of mortality among SAP patients in an ICU setting. In this study, the 
critically ill SAP patients who were treated in the medical ICU were not included. 
 
 
APACHE II and logistic regression models 
 
The current prognostic models are usually based on statistical regression analysis, as is the 
case for the APACHE II score (Knaus et al. 1985a), the Nottingham prognostic index of 
breast cancer (Haybittle et al. 1982), and a proposed model of survival for patients with 
primary melanoma (Schuchter et al. 1996). The APACHE II system is of only limited 
clinical utility for early prognostic evaluation of patients with SAP (Domínguez-4	5 
al. 1993). 
 
Artificial neural networks 
 
Artificial neural networks (ANN) have been successfully used for pattern recognition and 
survival prediction in several clinical settings (Lundin et al. 1999, Dubowski et al. 1996, 
Golub et al. 1998). ANNs offer a way of capturing nonlinearities and complex interactions 
between prognostic factors in a multivariable model (Burke 1996). Figure 1 shows the basic 
structure of a multilayer ANN (Lundin1998). 
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Figure 1 Basic structure of multilayer backpropagation neural network (multilayer 
perception) for outcome prediction (Lundin 1998) 
 
 
5.7.6 Other prognosticators 
 
The presence of retinopathy indicates a poor prognosis in patients with SAP (Hollo et al. 
1994). Some studies have shown that the gastric mucosal pH to predicts death in SAP 
(Bonham et al. 1997, Hynninen et al. 2000). 
 
5.7.7 Local complications of SAP 
 
Local complications increase the morbidity of SAP patients and may also increase the risk 
of a fatal form of SAP. Many of these complications occur in the late phase of the disease 
and are often treated conservatively.   
 
Intestinal 
 
It has been reported that SAP causes duodenal obstruction. However, total parenteral 
nutrition is associated with a good prognosis in patients with these lesions (Chen et al. 
2001). Ischemic strictures may form in the small intestine (Kato et al. 1998). Colon necrosis 
and strictures have also been described during SAP. Early detection and prompt surgery of 
lesions of the colon have been shown to improve patient outcome (Aldridge et al. 1989, 
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Kriwanek et al. 1996 and 1997, Fernández-Cruz et al. 1997, Umeno et al. 2000). 
Gastrointestinal fistulas are common in SAP patients who have undergone operative 
treatment of SAP (Ho et al. 1995, Kriwanek 1999). 
 
Vascular 
 
A variety of vascular complications have been reported in patients with SAP, including 
thrombosis of the portal vein (Dörffel et al. 2000). Pseudoaneurysm is a severe complication 
and carries a high risk of death. However, it can usually be treated with angiographic 
embolization or open operation with pancreas resection (Savastano et al. 1993, Sand et al. 
1997, De Perrot et al.1999). Patients with SAP may also develop arteriovenous fistulas, 
which can be treated surgically or using angiographic embolization (Raat et al. 1999). The 
percutaneous placement of a transgastric catheter for a pancreatic pseudocyst increases the 
risk of splenic artery pseudoaneurysms (Quinn et al. 1988). 
 
Pseudocysts 
 
Pseudocysts need treatment only if complications develop. Most pseudocysts disappear 
spontaneously; this is the case for 92% of the small cysts and the ones located in the 
pancreas tail (Maringhini et al. 1999). A pseudocyst can also cause obstructive jaundice 
(Fujita et al. 1996). Hastings et al. (1978) reported intrasplenic pancreatic pseudocysts in 
patients with SAP.  
 
Complicated pseudocysts can be treated with endoscopic, percutaneous or surgical 
procedures (Cooperman 2001a). Endoscopic management includes cystogastrostomy, 
cystoduodenostomy, cystojejunostomy, and transpapillary stenting (Vidyarthi and Steinberg 
2001). 
 
If pancreatic necrosis in a pseudocyst is unrecognized, infection can occur after radiological 
and endoscopic decompression of the pseudocyst (Hariri et al.1994). Complicated 
pseudocysts have previously been operated by pseudocystojejunostomy via open 
laparotomy (Bradley et al. 1979, Cooperman 2001b). Endoscopic (pseudocysto-
gastrostomy) and laparoscopic treatments of pseudocysts have also been reported (May et 
al. 1994, Oria et al. 2000, Schacter et al. 2000). Percutaneous catheter drainage is a well-
established method for treating pseudocysts and abscesses. Drainage of a cyst by a single- 
step needle drainage carries a recurrence rate of 70% or even more (Barkin et al. 1981, Neff 
2001). Also, fistulas may form after percutaneous drainage (Cooperman et al. 2001a). At 
Department of Gastroenterological and General Surgery, Meilahti hospital, the primary 
treatment of complicated pseudocysts is endoscopic (pseudocystogastrostomy or 
duodenostomy and, as required, stenting of ductus wirsingianus). If this treatment is 
unsuccessful, open surgery is needed (Baron et al. 2002). 
 
Other complications 
 
As a consequence of AP, perisplenic adhesions may form and cause spontaneous rupture of 
the spleen (Lukash 1967). Generalized heterotopic ossification has also been descibed in 
patients with SAP (Jacobs et al. 1999). 
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Various neurophysiological abnormalities may complicate the outcome of ICU treated 
patients (Coakley et al. 1998). Critical illness polyneuropathy (CIP) is defined as mixed 
motor and sensory disturbance. CIP may cause prolonged ICU and hospital stay and 
prolonged need of mechanical ventilation and it may increase the in-hospital mortality of 
septic patients with MOD syndrome requiring mechanical ventilation (Garnacho-Montero et 
al. 2001). CIP occurs frequently in patients with ICU treated SAP. But there are, no studies 
concerning the prognostic value of CIP in relation to hospital mortality in SAP patients.  
 
5.8 Hospital mortality of AP and SAP patients 
 
5.8.1 Mortality of AP patients 
 
The mortality rates of patients with AP vary from 2 to 9% (Mann et al. 1994, Grönroos et al. 
1999). According to the studies of Wilson et al. (1988a) and Appelros et al. (1999), 
pancreatitis was diagnosed only at necropsy in 42% to 52 % of the patients with fatal AP, 
while Mann et al. (1994) found that a diagnosis of pancreatitis can be established in 88% of 
patients with AP before death.  Early mortality from AP was high in reports from Scotland 
and USA (Renner et al. 1985, McKay et al. 1999). However, in a recent study early deaths 
of patients with SAP were rare: nine out of the ten deaths occurred later than 3 weeks after 
disease onset (Gloor et al. 2001). 
 
In studies in Turku covering the period 1971 to 1991 (Grönroos et al. 1999) and in 
Rotterdam 1985 to 1995 (Eland et al. 2000) the mortality trend of patients with AP did not 
decrease, while Bank et al. (2002) reported a reduction of mortality rates from 14% in 1978-
1982 to 4% in1998-2001 in New York. 
 
5.8.2 Mortality in SAP 
 
It is not feasible to compare the reported mortality rates in SAP, because most studies 
involve only a part of the SAP patients (e.g., patients with pancreatic necrosis, infected 
necrosis, sterile necrosis, with ICU treatment and organ or multiple organ failure). Also 
some studies include patients with a low risk of death. 
 
The mortality rate of patients with SAP has declined in the Meilahti hospital from 69-96% 
in 1967-1973 to 22-47% in 1979-1983 (Kivilaakso et al. 1981 and 1984). Rau et al. (1995) 
reported an overall mortality of 10% in a series of 172 patients with sterile necrosis in SAP; 
mortality was13% in the operatively treated group and 6% in the nonoperatively treated 
group. In a series of 30 patients with severe AP requiring treatment at an ICU, the mortality 
rate was 30% (Malcynsky et al. 1996). The survival of patients with necrotizing pancreatitis 
may be improving (Oleynikov et al. 1998, Kalfarentos et al. 1999). According to a recent 
study the mortality rates among SAP patients decreased from 50-58% in 1978-1982 to 12-
18% in 1993-1997 (Bank et al. 2002). 
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5.9 Long-term outcome after SAP  
 
5.9.1 SAP-related diseases  
 
Among patients who have recovered from necrotizing pancreatitis no less than 80-85% have 
persistent global or decreased pancreatic exocrine function (Bozkurt et al 1995) to an extent 
that varies with the degree of pancreatic parenchymal necrosis (Tsiotos et al. 1998). In 
earlier studies, 83-100% of the patients developed diabetes after distal resection of the 
pancreas for surgical treatment of pancreatic necrosis (Nordback and Auvinen 1985c, 
Schröder et al. 1990, Doepel et al. 1993). In the study of Büchler et al. (1987) half of the 
patients developed subclinical or overt diabetes mellitus after necrosectomy or closed 
lavation. Two studies have reported neuropathy symptoms in patients who have survived an 
attack of SAP. Occasionally, neuropathy persists and the patient becomes work-
incapacitated (Nordback and Auvinen 1985c, Gross et al. 1988).  
 
5.9.2 Quality of life  
 
In studies with a small number of patients, the quality of life (QOL), and outcome after 
SAP have been to be good (Doepel et al. 1993, Fenton-Lee and Imrie 1993, Broome et al. 
1996, Soran et al. 2000). However, only two studies regarding QOL assessment after SAP 
have used generic multidimensional measures. Two telephone surveys were carried out 
using the 36-item short-form general health survey. The first one consisted of 22 SAP 
patients who were operated on and the second one of 21 patients who were treated in an 
ICU. The results showed no statistically significant impairment in health-related quality of 
life (HRQL) (Broome et al. 1996, Soran et al. 2000).  
 
The Rand 36-item Health Survey is a generic multidimensional health-related quality of 
life (HRQL) measure considered to be an objective and reproducible instrument for the 
assessment of HRQL (Hays et al. 1993, VanderZee et al. 1996). The 15D instrument is a 
generic, comprehensive, 15-dimensional, standardized and validated measure of HRQL, 
developed in Finland. The 15D instrument is highly reliable and sensitive (Sintonen 2001). 
The 15D instrument has not been used in patients with SAP, while the Rand36 survey has 
been shown to have excellent psychometric properties in other populations and diseases 
and has also been evaluated in the measurement of long-term outcome of critically ill 
patients (Essink-Bot et al. 1997, Heyland et al. 2000, Pettilä et al. 2000). 
 
 
5.9.3 Return to work 
 
Doepel et al. (1993) recorded that, 24 of 31 (77%) ICU treated SAP patients returned to 
work. Similarly, in another Finnish study 19 of 24 (79%) SAP patients with pancreatic 
resection returned to work (Nordback and Auvinen 1985c). 
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6. PRESENT INVESTIGATION 
 
 
 
6.1 Aims of the study 
 
 
The general aim of this clinical study was to evaluate the outcome and quality of life of 
patients with SAP. 
 
 
The specific aims of this study were: 
 
 
1. To identify prognostic factors for hospital mortality in SAP by analyzing a large 
consecutive series of patients with SAP in a tertiary referral center. 
 
 
2. To construct multivariable predictive models to predict hospital mortality during the 
early phase of SAP, and to compare these models prospectively to previously reported 
predictive systems such as Ranson, Imrie, APACHE (Acute Physiology and Chronic 
Health Evaluation) II and Multiple Organ Dysfunction (MOD) score. 
 
 
3. To compare the MOD score, the Sequential (former Sepsis-related) Organ Failure 
Assessment (SOFA) score, and the Logistic Organ Dysfunction (LOD) score as 
predictors of hospital mortality, and to use one of these scores to assess the incidence 
and prognostic significance of organ dysfunction/failure in patients with SAP treated in 
a general intensive care unit (ICU). 
 
 
4. To assess the long-term health-related quality of life (HRQL) after SAP with the 
RAND 36-item Health Survey, and to compare the HRQL of patients with SAP and 
some subgroups of SAP with that of the general population. An aim was also to define 
the overall long-term post-discharge outcome of patients after SAP. 
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6.2 Patients 
 
The total number of episodes of AP in the study hospital during the 10 years study period 
was 1539 of which 317 (21%) were SAP. Patients with SAP who were admitted to the 
Second Department of Surgery at the Helsinki University Central Hospital from January 
1989 through December 1998 were included in the study. The study periods and the 
characteristics are presented in Table 1. The demographic and clinical characteristics of the 
overall study population and patients in studies III-IV are shown in Table 2.  
 
6.2.1 Definition of SAP 
 
1)     Low contrast enhancement of the pancreas (below 50 Hounsfield units) on contrast-
enhanced computed tomography (Kivisaari et al. 1983 and Balthazar et al.1985, 1990, 
1994) and CRP concentration above 120 mg/L within 48 h of admission (Büchler et al. 
1986, Puolakkainen et al. 1987, Wilson et al. 1989)  
 
2) Necrotizing pancreatitis at autopsy  
 
3) Histologically confirmed necrosis discovered during surgery 
 
4)  Respiratory and renal organ failure requiring mechanical ventilation and dialysis, 
respectively, with hyperamylasemia (3 times the upper limit of the reference range) 
and CRP over 120mg/L within 48 h of admission 
 
At least one of the criteria above had to be fulfilled for inclusion of a patient in the study. 
All patients in my study fulfilled the Atlanta criteria for SAP (Bradley 1993). 
 
 
6.2.2 Definitions of causes of SAP 
 
Alcohol-related disease was assumed if there was a clear history of frequent alcohol 
consumption or alcohol excess immediately before the attack of AP and when no other 
etiologic factors were identified. Gallstone-related disease was based on the identification of 
gallstones by radiological examinations (sonography, ERCP, computed tomography or 
magnetic resonance imaging). Post-operative and post-ERCP pancreatitis was assumed if 
the disease occurred within a week after the procedure. 
 
6.2.3 Study patients 
 
In study I, 270 consecutive patients admitted to study hospital from January 1989 through 
October 1997 with SAP were included in to the study. 
 
In study II, the hospital records of 253 patients with SAP admitted to the study hospital 
from January 1989 through April 1997 were retrospectively analyzed for constructing the 
predictive models. Nineteen patients had insufficient data on one or more of the variables 
and were excluded, leaving 234 eligible patients to the test set. An independent validation 
set consisted of prospectively collected data during the first 72 hours of 60 consecutive SAP 
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patients with primary or transferral admission to the study hospital from May 1997 through 
December 1998. The patient characteristics in the test and validation sets are shown in 
Study II, table 1 page 311. 73% of the patients in the test set and 75% of the patients in the 
validation set were admitted within less than 24 h after the first symptoms of AP and a 
maximum delay of 48 h from onset of symptoms to admission was recorded in 88% of the 
patients in both sets. The number of operated patients in the test and validation set was 84 
(36%) and 16 (27%), respectively. The mortality rates in these groups were 41% and 50%, 
respectively. No significant difference was found between the test and validation sets.  
 
In study III, the hospital records were retrospectively analyzed for 178 consecutive patients 
with SAP admitted to the study hospital from January 1994 through December 1998. Of 
these, 113 were treated in a 10-bed general intensive care unit (ICU). The criteria for 
general ICU treatment were progressive organ dysfunction. Of the 65 patients with SAP not 
treated in the general ICU, but in the surgical ICU, only four died (6%). The characteristic 
of these patients are shown in study III, page 1275. 
 
In study IV, the hospital records of 283 consecutive patients with SAP admitted to study 
hospital from January 1989 to December 1997 were analyzed retrospectively. Of these 72 
(25%) died during hospitalization and 27 (10%) died 7-115 months after discharge during 
the follow-up period (mean 66). A causes of death were recorded from the Central 
Statistical Bureau of Finland and are shown in study IV, page 783. Seven patients with 
unknown addresses and three with limited cultural or mental abilities to complete the 
questionnaire were excluded, and thus questionnaires were sent to 174 patients. Of these, 
145 returned the questionnaires (83% response rate) and comprised the final study 
population. The characteristics of all survivors of SAP are presented in Study IV, in table 1 
(page 783). 
 
 
      
 Table 1 
Study characteristics of episodes of severe acute pancreatitis (SAP) 
  
  
  Number of Time Inclusion  Number of 
  episodes of SAP period criteria included episodes 
      
 I Study 270 1/1989 to 10/1997  SAP 270 
      
 II Study 317 1/1989 to 12/1998 SAP and sufficient data 294 
   Test set 253 1/1989 to 4/1997  234 
   Validation set 64 5/1997 to 12/1998  60 
      
 III Study 178 1/1994 to 12/1998 SAP and ICU treatment 113 
      
 IV Study 283 1/1989 to 12/1997 SAP and alive 8/1999 174a 
      
 
aExcluded 7 patients with unknown addresses and 3 patients with limited linguistic or mental abilities 
 to complete the questionnaire. ICU = intensive care unit.   
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 Table 2 Demographic data for 317 consecutive episodes of   
   severe acute pancreatitis (SAP)     
      
  All Study III Study IV  
      Surveya No Survey 
      
 
Number of episodes of SAP 317 113 145 39 
      
 
Male sex (%) 265 (84) 100 (89) 120 (83) 35 (90) 
 
 
    
 
Mean age (range) 46 (16-83) 46 (16-83) 44 (20-78) 43 (21-83) 
      
 
Alcohol etiology (%) 245 (77) 90 (80) 113 (78) 35 (90) 
      
 
Mean length of hospital stay, days (range) 38 (2-212) 45 (2-208) 39 (10-212) 29 (10-144) 
      
 
Mean length of ICU stay b, days (range) 19 (0-149) 26 (1-77) 17 (0-94) 14 (0-74) 
      
 
Required general ICU treatment (%) 194 (61.2) 113 (100) 76 (52) 18 (46) 
 
a
 Fulfilled Finnish version of the Rand 36-item Health Survey 1.0 questionnaire. ICU = intensive care unit. 
 
b
 Include both surgical and general ICU. 
  
 
 
6.3 Methods and data collection 
 
6.3.1 Assessments of multiple organ dysfunction 
 
The MOD syndrome was first described as a sequential system failure in 1973 (Tilney et al. 
1973). The mortality rate has ranged from 20 to 100%, depending on the number of organ 
involved, severity, duration, type, and combination of organ failures, as well as definition 
(Knaus et al. 1985b, Tran et al. 1993a, Zimmerman et al. 1996). 
 
There are indeed numerous ways to define and score MOD (Fry et al. 1980, Pine et al. 1983, 
Goris et al. 1985, Knaus et al. 1985b, Fagon et al. 1993, Hebert et al. 1993). The three more 
recent scores are the Multiple Organ Dysfunction (MOD) score (Marshall et al. 1995), the 
Sequential (formerly termed Sepsis-related) Organ Failure Assessment (SOFA) score 
(Vincent et al. 1996 and 1998), and the Logistic Organ Dysfunction (LOD) score (Le-Gall 
et al. 1996) which are designed to assess the severity and development of multiorgan 
dysfunction as a single score. A comparison of the values of Multiple Organ Dysfunction 
Score (MODS), Logistic Organ Dysfunction System (LOD), and Sequential System 
Assessment (SOFA) are shown in table 3. 
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Table 3.  Comparison of values of Multiple Organ Dysfunction Score (MODS), Logistic Organ Dysfunction 
System (LOD), and Sequential System Assessment (SOFA) 
 
Organ system /score 0 1 2 3 4 5 
 
      
Respiratory       
  PO2/FIO2, mmHg       
    SOFA >400 300-399 200-299 100-199a <100a  
    MODS >300 226-300 151-225 76-150 <76  
    LOD       
         On MVbor CPAPc     <150   
 
No Ventd and      
 
No CPAPc       
 
No  IPAPe      
Renal       
	 
 	       
    SOFA <110 110-170 171-299 300-440 >440  
          Or urine output, L/day    or <0.5 or <0.2   
    MODS  101-200 201-350 351-500 >500  
    LOD <106 and 106-140      
          Serum urea, mmol/L <6 and or 6-9.9  or 10-19.9    
          Urine output, L/day 0.75-9.99   or >10  <0.5 
          Serum urea nitrogen mmol/L and <6  or 6-9.9  or 10-19.9    
Hepatic       
   Serum bilirubin, mol/L       
    SOFA <20 20-32 33-101 102-204 >204  
    MODS  21-60 61-120 121-240 >240  
    LOD <34.2 and        
          And protombin time%   <25%     
Cardiovascular       
     SOFA       
       Mean arterial pressure, mmHg >70  < 70     
       Adrenergic agents, g/kg/minf   Dopg <5 Dopg 5-15 Dopg >15  
                                          Or    Dobhny dose Epinepi <0.1 Epinepi >0.1  
                                          Or     Norepj <0.1 Norep>0.1  
    MODS       
       PARk  10.1-15.0 15.1-20.0 20.1-30.0 >30.0  
    LOD       
       Heart rate, beats/min 30-139 and >140 or    <30 or 
       Systolic blood pressure, mmHg 90-239 70-89 or  40-69 or  <40 
  240-269      
Hematologic       
   Platelet count x 109/L       
    SOFA >150 100-150 50-99 20-49 <20  
    MODS >120 81-120 51-80 21-50   
    LOD          
       White blood cell count x 109/L 2.5-49.9 1.0-2.4  <1.0   
  or       
Neurologic       
  Glasgow Coma Scale       
     SOFA >14 13-14 10-12 6-9 < 6  
     MODS 15 13-14 10-12 7-9   
     LOD 14-15 9-13  6-8  3-5 
a
 with respiratory support. b mechanical ventilation. c continuos positive airway pressure. d ventilation. e intermittent positive 
airway pressure. f adenergic agents administered for at least one hour. g dopamine. h dobutamine. I  epinephrine.  
j
 norepinephrine. k=heart rate x right atrial or central venous pressure / blood pressure 
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6.3.2 Definition of organ and multiple organ failure 
 
Organ failures were defined as a SOFA score of any organ of >3 of 4; PaO2/FiO2 <200 (mm 
Hg) for respiratory failure, platelets x 109/L <50 for coagulation, bilirubin >102 (µmol/L) 
for liver, epinephrine or norepinephrine administered for (! or dopamine administered for 
(!  0723
8  & +	 9   :!. &  +	
system, and creatinine >300 (µmol/L) or urine output <500 mL/day for  renal failure 
(Vincent et al. 1996). MOF was defined as the failure of at least two organs in the SOFA 
score for any organ of >3 of 4. 
 
6.3.3 Assessment of quality of life 
 
The Rand 36, a generic multidimensional HRQL measure, consists of 36 questions divided 
into eight domains, each measured by responses to groups of two to ten items on a scale 
from 0 (poorest) to 100 (best). Rand 36 and its Finnish version are based on the Medical 
Outcomes Study 36-item short-form health survey (SF-36) (Machorney et al. 1993, Aalto et 
al. 1999). This questionnaire includes questions related to physical and to mental health. 
Questions regarding physical health include physical functioning, role limitations because 
of physical problems, bodily pain, and general health. Mental health variables include 
vitality, social functioning, role limitations because of emotional problems, and mental 
health. The items, scoring rules, and permission to use the Rand 36 questionnaire are readily 
available in English via the Internet. (http://www.rand.org/health/surveys/sf36item/) 
(Anonymous 2002).   
 
6.3.4 Data collection 
 
Retrospective data collection included: age, gender, etiology (alcohol/nonalcohol), history 
of previous AP (first/recurrent), chronic medication, primary or referral admission, height 
and weight on admission for body-mass-index (BMI) calculation, need of mechanical 
respiration support, use of vasoactive drugs, renal failure, abdominal surgery performed 
during hospitalization, length of hospital stay and length of stay in the general or surgical 
ICU.  
 
In study II the highest leukocyte value, the highest CRP value, the lowest hemoglobin 
value and the highest hemoglobin value during the first 72 hours were also collected. The 
serum creatinine value was measured within 60-72 h of admission to make adequate fluid 
replacement for dehydration possible. 
 
In study III the data collection on the 113 patients who had general ICU treatment included 
also the presence of intra-abdominal infection, infection of pancreatic necrosis, white blood 
cell and platelet counts, plasma potassium and sodium concentration, blood gas analysis, 
blood hemoglobin, hematocrit, prothrombin time, temperature, Glasgow coma scale, 
respiratory rate, inspiratory oxygen fraction, blood pressure, mean arterial pressure, heart 
rate, central venous pressure, daily urine output, serum creatinine, urea, albumin, and 
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bilirubin concentrations. In study IV the presence of diabetes, diarrhea, abdominal pain, 
recurrent pancreatitis, symptoms of polyneuropathia, and MOF were also collected.  
 
For analysis, the patients with alcohol-induced AP formed one group and the patients with 
non-alcohol AP another group. My definition of a patient having a comorbid disease was 
the need for chronic medication. Patients were assumed to have comorbid disease when a 
prescription for chronic medication had been made before admission to the hospital 
regardless of whether they used the medication or not. In study II the history of chronic 
medication was subdivided into different groups according to underlying diseases [asthma, 
diabetes, prophylaxis for thromboembolism, cardiovascular disease (e.g., diuretics, 
antihypertensive drugs, digoxin), other diseases and disease combinations].  
 
The body-mass index (BMI) was calculated as weight (kg)/height2 (m2). In study I eight 
patients with inadequate data on height and/or weight were excluded from multivariate and 
univariate analysis on BMI. Mechanical ventilation (except for anesthesia required for 
surgery), dialysis, or need of vasoactive pressor drugs at any time during hospitalization 
was considered positive for that these respective variables. Abdominal surgery during 
hospitalization included both early explorative laparotomy for acute abdomen as well as 
planned procedures for AP.  
 
The presence of infected necrosis was determined by culture of computed tomography- 
guided percutaneous aspiration (Gerzof et al. 1987) or pancreatic tissue derived at surgery. 
The presence of intra-abdominal infection was considered positive if there was infected 
necrosis or positive culture from specimens taken from an abdominal drainage tube or from 
abdominal ascites. 
 
6.3.5 Study methods  
 
In study I, univariate and multivariate logistic regression analysis was performed using 
hospital mortality as the end-point. Univariate analysis was performed with 11 variables. 
Multivariate logistic regression analysis was performed on the data from 262 patients for all 
variables as well as the variables available on admission (age, gender, etiology, number of 
previous AP, previous medication history, type of admission and BMI). 
 
In study II, univariate logistic regression analysis was performed on the test set to evaluate 
single prognostic factors for hospital mortality during the first 72 h (results are seen in 
Study II, table 2, page 311). The information from the test set analyses of single prognostic 
factors was used to create five logistic regression and three ANN prediction models (LR4, 
ANN4, LR4*, LR5, LR5*, ANN5, LR8, and ANN8 which are shown in study II, in table 3, 
page 312. Three prediction models (LR5, LR5*, and ANN5) were first constructed with all 
independent prognostic factors. The admission variable was considered too unreliable and 
dependent on local circumstances and was, therefore, excluded. The predictive power of the 
need for mechanical ventilation and the need for pressor support were almost equal. 
However, the predictive accuracy of the former was statistically more significant and was 
chosen for the LR4, ANN4, LR4*, LR8, and ANN8 models. Two prediction models (ANN8 
and LR4) were chosen to generate survival estimates in an independent validation set. The 
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ANN8 model with eight variables had the highest accuracy. The LR4 model had almost the 
same accuracy as ANN8 and was the simplest with four variables. These two models were 
compared for predictive accuracy with the established prognostic systems Ranson (1982), 
Imrie (Blamey et al. 1984), APACHE II (Knaus et al. 1985a, Wilson et al. 1990), and MOD 
score (Marshall et al. 1995). 
 
In study III, the APACHE II score (Knaus et al. 1985a, Wilson et al. 1990) was calculated 
from the data from the first 24 hours spent in the general ICU’s. Missing data were 
considered to be normal. The organ dysfunction scores (MOD, SOFA, LOD) were 
calculated for the first 24 h of general ICU stay and for days 3, 7, 14, 21, 28, and 35 after 
primary admission to the hospital. If a laboratory value was missing, the previous day’s 
value was used, and if that value was not available, the next day’s value was used. If both of 
these were missing, the value was considered missing data and calculated as a normal value. 
Organ dysfunction scores were calculated until the patient died or was transferred without 
any organ dysfunction to a surgical ward. For all scores, the Glascow coma scale was 
considered to be normal in sedated patients, if there was no known cause for abnormality. In 
order to achieve better comparability among SOFA, MOD, and LOD scores, the scores were 
calculated for each day by use of the worst single values for that day, not the worst value for 
the entire hospital stay, which has been validated in previous studies (Marshall et al. 1995). 
Maximum scores for daily values and total maximum scores (sum of the highest values for 
each organ dysfunction) were calculated for all three organ dysfunction scores. To assess 
the incidence and the prognostic usefulness of organ dysfunction/failure, I calculated 
individual organ scores separately by using the SOFA score for first 24 h of general ICU 
stay and for days 3, 7, 14, 21, 28, and 35 after primary admission to the hospital. The 
highest value on these days was considered as the maximum organ dysfunction score.  
 
In study IV, the validated Finnish version (Aalto et al. 1999) of the Rand 36-item Health 
Survey 1.0 (Hays et al. 1993) questionnaire with accessory questions regarding subjective 
overall assessment of professional status, symptoms, medication, and living status, was 
mailed to patients for self-administration. If there was no initial response to the 
questionnaire, the patients were contacted twice again by mail or by phone, and the 
questionnaire was resent to ensure a maximal response rate. Readmissions and outpatient 
visits until August 1999 was reviewed from the hospital records. Further analysis was 
performed with the following subgroups: patients with or without MOF, with or without 
general ICU treatment and those having undergone abdominal surgery or not treated 
operatively. 
 
6.4 Statistical analyses 
 
 
In study I, age and BMI were analyzed as continues variables, and the other variables were 
dichotomous. Univariate and multivariate logistic regression analysis (Stat View; SAS 
Institute, Cary, N.C., USA) was performed using hospital mortality as the end-  ;2- 
test was used to test for associations between variables. A p-value less than 0.05 was 
considered statistically significant. In the tests for associations between variables, the cut-
off for age was 43.5 years (median) and for BMI 28. 
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In the study II, the area under the receiver operating characteristic curve (AUC) was used 
as a measure of accuracy of the predictor models in separating survivors from nonsurvivors 
(Metz 1978). In the logistic regression analyses (Stat View; SAS Institute, Cary, N.C., 
USA), a p-value of 0.05 was adopted as a limit for significance and inclusion of a covariate. 
 
The artificial neural networks were constructed using a freely available computer program 
(Nevprop 4, www.scsr.nevada.edu/nevprop/; Dr. Philip Goodman, University of Nevada, 
Reno, Ne.V., USA). All three ANN models were feed-forward three-layer models with a 
learn rate of 0.01 and weight decay –0.001.The chosen ANN8 model had eight hidden 
nodes. A pure gradient descent, globally adaptive learning rule was used to optimize the 
network. Sigmoid transfer functions were used in the hidden layer and in the output layer. 
Network output ranged from 0 to 1. The log likelihood (cross-entropy) was used as the error 
function and train criterion for the input. A holdout data set of 40 % of the patients and a 
five-fold cross-validation were used to assess the error criterion of the model during the 
process of optimization. The data set was bootstrapped 50 times to estimate the optimistic 
bias due to overtraining and to correct the accuracy measures accordingly. 
 
In study III, data are presented as mean ± SE or median (range). In all comparisons, p< 
0.05 (two-tail) was considered significant, and the Mann-Whitney rank sum test was used. 
Predictive values for the various scores regarding hospital mortality were evaluated. AUC 
(SE) served as a measure of discrimination (ability to distinguish between patients who die 
and those who survive) of organ dysfunction scores. Multiple logistic regression analysis 
was performed regarding hospital mortality. Statistical tests were performed with the BMDP 
1.1 version for Windows (BMDP Statistical Software, Cork, Ireland), SPSS 9.0 for 
Windows (SPSS, Chigaco, IL, USA), and GraphROC 2.0 for Windows [Turku, Finland 
(Kairisto and Poola 1995)]. 
 
In study IV, the results were expressed as means ± SD (median). For comparisons, the 
norms of the Finnish population were adjusted for distribution by age and sex of the study 
patients and separately for the subgroups. These scores were compared with the study 
population by the non-parametric Mann-Whitney U test. Results of HRQL were also 
converted to Z scores (standard deviation unit), in which the Z score is the patient mean 
score minus the adjusted Finnish population score divided by the standard deviation for the 
Finnish population (Weinert et al. 1997). If the means differed by more than 10 and the Z 
score more than 2, these were considered clinically significant (Pettilä et al. 2000). Multiple 
linear regression analysis was performed to identify variables independently associated with 
HRQL domains. 
 
6.5 Results 
 
6.5.1 Hospital mortality in SAP 
 
The overall hospital mortality rate for the patients with 317 episodes of SAP was 26%. The 
mortality rate of patients treated in the general and surgical ICU was 25%, and for those 
treated with general ICU alone 36%. The mortality rates of patients with MOF and early 
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MOF were 49% and 64%, respectively. The mortality rates in the different subgroups are 
presented in table 4. 
 
6.5.2 Prognostic factors for hospital mortality in SAP 
 
As shown by table 1 and 2, in study 1, in pages 268-269 the independent prognostic factors 
for hospital mortality were advanced age, history of continuous medication, renal, 
respiratory or cardiovascular failur, while gender, etiology, first vs multiple episodes of 
AP, type of admission, BMI or abdominal surgery were not. The independent prognostic 
factors according to logistic regression analysis for variables available on admission were 
referral admission, advanced age and chronic medication (results are shown in Study I, in 
table 3, page 269). The numerous associations between variables are shown in Study I, in 
table 4, page 270. 
 
The statistically most significant combination of medication variables by univariate survival 
analyses in study II was the history of chronic cardiovascular and/or anticoagulation 
medication (relative hazard RH 4.510, confidence interval CI 2.314-8.791, p<0.0001). By 
multivariate logistic regression analysis in the test set in study II, the independent prognostic 
factors turned out to be advanced age, history of chronic cardiovascular and/or 
anticoagulation medication, high serum creatinine value within 60-72 h of admission, 
transferal admission, and either a need for mechanical ventilation during the first 72h of 
admission or a need for vasoactive pressor drugs during the first 72 h of admission. Results 
from multivariate logistic regression analysis are seen in Study II, in table 3, page 312. 
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Table 4                                   Comparison of mortality of different subgroups during a 5-year   
   
period of patients wih 317 episodes of severe acute pancreatitis 
(SAP) 
    
  1989- 1993 1994- 1998 1989- 1998  
  Number of Mortality Number of Mortality Number of number of Mortality 
  episodes % episodes % episodes deaths % 
   of SAP    of SAP    of SAP     
  139 25 178 26 317 81 26 
 Gender        
    Male 116 22 149 26 265 64 24 
    Female 23 35 29 31 52 17 33 
 Age        
     Over 60 years 15 47 31 48 46 22 48 
     Under 60 Years 124 22 147 22 271 59 22 
 Etiology        
    Alcohol 112 21 133 25 245 57 23 
    Non-alcohol 27 37 45 31 72 24 33 
 Type of admission        
    Hospital transfer 84 33 110 32 194 63 33 
    Primary admission to study hospital 55 11 68 18 123 18 15 
 History of cardiovascular medication        
    Yes 34 53 58 43 92 43 47 
    No  105 15 120 18 225 38 17 
 Organ failure        
   Yes 82 42 111 29 193 79 41 
    No 57 0 67 3 124 2 2 
 Single organ failure 21 0 13 8 34 1 3 
 Multiple organ failure        
    Yes 60 57 98 45 158 78 49 
    No 79 0 80 4 159 3 2 
 Early* organ failure        
    Yes 47 62 74 46 122 64 53 
    No 92 5 104 13 195 18 9 
 Early* multiple organ failure        
    Yes 34 74 50 58 84 54 64 
    No 105 9 128 14 233 27 12 
 Abdominal infection#        
    Yes   48 56    
    No   130 15    
 Peripancreatic necrosis infection¤        
    Yes   28 46    
    No   150 23    
 Abdominal operation 48 35 61 49 109 47 43 
    Emergency operation 14 50 16 38 30 13 43 
    Planned local peripancreatic 40 33 52 52 92 40 44 
 
   Emergency operation+planned 
oper. 8 38 10 40 18 7 39 
    No operation 91 19 117 15 208 34 16 
                 
 
Organ failures were defined as a SOFA score for any organ of >3 of 4.  Multiple organ failure was defined as the failure at least 
two organs in the SOFA score for any organ of >3 of 4. * before 72 hours from admission. # infected necrosis or positive culture  
 
from abdominal drainage tube or ascites. ¤ positive culture from percutaneous aspiration or pancreatic tissue debrided at surgery. 
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6.5.3 New models to predict a fatal outcome in SAP 
 
The two new models (LR4 and ANN8) had a better predictive performance than the 
Ranson, Imrie, Apache II, and MOD scores. There were statistically significant differences 
in predictive accuracy between my two models and the Ranson and Imrie scores, as is seen 
in table 5. The LR4 model had a better accuracy than the ANN8 model and was chosen as 
the optimal model. 
 
 
       
 
 
Table 5.  Predictive values of the novel prediction models in the prospective validation set 
compared with Ranson, Imrie, APACHE II and MODS system in 60 consecutive patients  
with severe acute pancreatitis  
 
       
 
 LR4a ANN8b Ranson Imrie APACHEc II MODSd 
 
Mean (±SD) 0.34(0.27) 0.38(0.33) 5(1.8) 4(1.7) 10(10.4) 6(5.7) 
 
Sensivity (%)e 88 82 65 94 65 59 
 
Specificity (%)e 88 88 70 28 91 91 
 
AUCf (accuracy) 0.86 0.85 0.66 0.54 0.82 0.78 
 
Cl 95%g 0.76-0.96 0.74-0.95 0.50-0.81 0.36-0.71 0.70-0.93 0.66-0.90 
 
Spec at 88 sensh 88 74 79 28 42 40 
 
Sens at 88 speci 88 82 24 6 65 65 
 
P-values LR4 vsj  0.74 0.01 0.001 0.46 0.22 
 
 
      
 
alogistic regression predictive model with 4 variables. bartificial neural network predictive model with 
8 variables. cAcute Physiology and Chronic Health Evaluation. dMultiple Organ Dysfunction Score. 
emodel's sensivity and specifity in best spot. farea under curve. gconfidence interval at 95%level. 
hsystems specifity at 88% sensivity level. isystems sensivity at 88% specifity level. j2-tailed (p)-value  
comparing the novel logistic regression prediction model's AUC values to other systems.                    
 
The chosen logistic regression model (LR4) has four variables: age (RH 1.05, p<0.004), 
history of chronic cardiovascular and/or anticoagulation medication (RH 2.545, p<0.021), 
need for mechanical ventilation during the first 72 h (RH 2.973, p<0.005) and highest serum 
creatinine value within 60-72 h of admission (RH 1.006, p<0.0001). 
 
The regression equation for the LR4 model is: 
 
Logit (p) = -4.77 + 0.045 x age + 0.934 x history of chronic cardiovascular and/or 
anticoagulation medication + 1.090 x mechanical ventilation during the first 
72 h of admission + 0.006 x highest serum creatinine value between 60-72 h 
of admission 
 
Example:     A 61-year-old man with antihypertensive medication, mechanical ventilation 
from the second day after admission and a serum creatinine value of 350 
µmol/l 72 h after admission would have the following probability of death: 
Logit (p) = loge [p/(1-p)] = -4.765 + 0.045 x 61 + 0.934 + 1.090 + 0.006 x 350 
= 2.104. p=elogit(p)/(1+elogit(p)) = 0.89. Thus, the patient has an 89% risk of 
dying from this episode of SAP. 
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6.5.4 Multiple organ dysfunction associated with SAP 
 
 
In study III, 41 of 43 nonsurvivors died of MOF. The other two patients died of cerebral 
infarction with respiratory failure, and myocardial infarction with respiratory failure, 
respectively. The median APACHE II score for the first 24 hours at the general ICU was 11 
(range 0-32) and the AUC value for the APACHE II score in predicting hospital mortality 
was 0.773 (SE 0.1). 
 
Daily maximum SOFA scores of survivors and nonsurvivors among 113 patients with SAP 
treated in intensive care unit are shown in Figure 2. 
 
 
 
Figure 2 The daily maximum SOFA scores of the survivors and nonsurvivors among 113  
 patients with severe acute pancreatitis treated in an intensive care unit   
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The results of the SOFA, MOD and LOD scores for predicting hospital mortality and daily 
maximum values are presented in Study III, in Figure 1, page 1276. The SOFA scores had 
the highest discrimination values and the daily organ maximum scores the highest 
discrimination. Survivors achieved the maximum mean daily SOFA score on day 7 (6.7, SE 
6.7) and nonsurvivors on day 14 (12.2, SE 4.8). Figure 3 shows how the mean daily SOFA 
scores changed in these subgroups. 
 
 
 
 
Figure 3. Mean (CI 95%) daily Sequential Organ Failure Assessment (SOFA) score in 113 
patients with severe acute pancreatitis treated in an intensive care unit 
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The mean maximum neurological (2.0, SE 1.7), renal (1.3, SE 1.7), and respiratory (2.5, SE 
1.0) dysfunction scores were reached on day 14. The maximum mean of scores for 
cardiovascular (1.4, SE 1.6), coagulation (1.3, SE1.0), and liver (1.0, SE 1.1) organ 
dysfunction were reached on the third day (Figure 4).  
 
Figure 4   Development of organ dysfunction by mean (95% CI) Sequential Organ Failure 
Assessment (SOFA) scores (range 1-4) in 113 patients with severe acute 
pancreatitis treated in an intensive care unit 
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Mortality rates for patients with single maximum organ dysfunction in the subgroups of no 
dysfunction (SOFA 0), mild dysfunction (SOFA 1 or 2), and organ failure (SOFA 3 or 4) 
were highest when associated with hepatic (83%, p<0.001) and renal (63%, p<0.001) 
failures (Figure 5). The prevalence rates of patients without organ failure, with only one 
organ failure, with 2 to 3 organ failures and with 4 to 6 organ failures were 12%, 10%, 35%, 
and 43%, and the mortality rates 0%, 18%, 20%, and 69%, respectively. 
 
 
 
 
                
Figure 5 Maximum SOFA organ score (from d3, d7, d14, d21, d28 and d35 values) and  
 hospital mortality for 113 patients with severe acute pancreatitis treated in   
  an intensive care unit                      
                
   Hepatic Renal  Coagu- Cardio- Neuro- Respira-  
       lation  vascular logic  tory   
 Mortality   22%   6%   28 %  5%   0%   0%    
SOFA 0   
 
         
  
         
 
 Patients     36   48  25   21   18   2 
                
 Mortality   34%   56%   38%   20%   19%   13%    
SOFA 1-2 
  
  
                  
 
 Patients     69   16   72   25  16  15 
                
 Mortality   83%   63%   56%   55%   51%   43%    
SOFA 3-4 
  
  
                  
 
 Patients     18   49  16   67  79  96 
                
                
 
 
 
 
Regarding the hospital mortality rates for different combinations of two organ system 
failures, mortality was highest (91%) among patients with a combination of hepatic and 
renal failures (Figure 6). By multiple logistic regression analysis, only hepatic failure (OR 
13.0), renal failure (OR 5.6), previous chronic cardiovascular medication (OR 4.7), and 
cardiovascular failure (OR 4.7,) were associated independently with hospital mortality. In 
contrast to the overall results of this study, this model (Nagelkerke R^2 0.53; Goodness of 
Fit 0.10) did not identify age, etiology, respiratory failure, coagulation failure, neurological 
failure or infection of pancreatic necrosis as independent risk factors for hospital mortality. 
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 Figure 6 Hospital mortality rates for different combinations of two organ system failure 
 (maximum organ SOFA score 3 or 4) for 113 patients with severe acute   
  pancreatitis treated in an intensive care unit            
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Patients with a history of chronic cardiovascular and/or anticoagulation medication had a 
mortality rate of 62% (p<0.001), and all patients in this category with a daily maximum 
SOFA >15 died (12 patients). Twenty patients had a history of chronic cardiovascular 
and/or anticoagulation medication and had renal dysfunction on day 3 and a mortality rate 
of 85% (p<0.001); 14 of these patients with SOFA scores from 2 to 4 died. The mortality 
rates for the patients with infected pancreatic necrosis (27 patients) and intra-abdominal 
infection (46) were 48% (NS) and 54% (p<0.003), respectively. 
 
Age had an AUC value of 0.65 (SE 0.15) for hospital mortality. The mortality rates for 
patients with SAP who were <45 years old and had a daily maximum SOFA score <10 (28 
patients), a SOFA score between 10 and 15 (15), and a SOFA score >15 (13) were 0%, 
20%, and 85%, respectively. Of patients >60 yrs old, nine had daily maximum SOFA scores 
>10, with a mortality rate of 100%, and eight had daily maximum SOFA scores <10, with a 
mortality rate of 38%. 
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6.5.5 Long-term health-related quality of life of survivors from SAP 
 
 
The HRQL measured by the Rand 36 survey of patients after SAP is presented in table 6. 
Of the 145 patients, 76 (52%) stated that their general health was about the same or better 
than before SAP. There was no clinically significant difference between the study group or 
subgroups (patients with vs. without general ICU treatment, MOF, and surgery), and an the 
general Finnish population matched for age and sex. 
 
 
Table 6 Health-related quality of life according the RAND 36 test (mean) for 145 patients with severe  
 acute pancreatitis (SAP) compared with the age- and sex-matched general population 
  (POP)                           
 G H P F B P R P V I S F R E M H 
 SAP POP SAP POP SAP POP SAP POP SAP POP SAP POP SAP POP SAP POP 
All (145 patients) 51 60 83 83 73 74 69 72 60 65 76 81 68 75 68 74 
Median 50 65 90 87 76 73 81 82 70 65 80 77 100 76 100 75 
SD  21 8 22 12 22 3 28 5 23 6 28 7 38 14 39 8 
p-valuea <0.001   0.23   0.53   0.72   0.34   0.39   0.11   0.14   
Z-scoreb 1.16   0.08   0.10   0.23   0.76   1.0   0.89   1.73   
 
GH= general health. PF= physical functioning. BP= bodily pain. RP= role limitations because of physical problems. 
VI= vitality. RE= role limitations SF= social functioning because of emotional problems.  MH=mental health. SD= 
standard deviation. a Man-Whitney U test. bpatient mean score minus adjusted Finnish population score divided by 
standard deviation of the Finnish population. 
 
The HRQL domains were not independently associated with follow-up time, cause, gender, 
general ICU treatment, duration of general ICU stay, MOF or operating status by 
multivariate regression analysis. On the other hand, the working status before SAP was 
independently associated with physical functioning (p=0.04), social functioning (p=0.04), 
vitality (p=0.04), role limitations because of physical problems (p=0.005), and role 
limitations because of emotional problems (p=<0.001). Age at time of analysis was 
independently associated with physical functioning (p=<0.001) and with role limitations 
because of physical problems (p=0.010). 
 
Of all survivors, 175 patients had the opportunity to return to work (patients >63 yrs old 
and those who were known to be retired before SAP were excluded). Of these, 61% did 
return to work. Of the 145 patients in the study population, 68 % were working during the 
year before onset of SAP; 69% of them returned to work and 60% were working at the time 
of the study. Of the patients who were working during the year before onset of SAP, 87% 
  
55 
55 
returned to work and 70% were working at the time of the study. There were no 
statistically significant differences between the subgroups. 
 
The long-term morbidity after SAP is presented in table 7. 37% of the patients developed 
diabetes during hospitalization for a SAP attack. During the follow-up period, 47% of the 
patients developed diabetes. The rate for developing diabetes among the 8 patients with 
pancreatic resection and the 31 with digital necrosectomy was 100% and 52%, 
respectively. By posthoc subanalysis, patients with diabetes did not differ significantly with 
respect to any HRQL domain from the patients with no diabetes. During the study period, 
43% of the patients had diabetes, 45% of them had also numbness in their lower or upper 
limbs, compared to the 40% with alcohol-induced SAP. Polyneuropathia symptoms among 
the other subgroups are presented in table 7. 
 
 
       
 
 
Table 7               Complications and symptoms (%) of 145 patients who  
                            survived severe acute pancreatitis (SAP) 
  Recurrent    Abdominal 
  pancreatitis Diabetesa Neuropathyb Diarrheac Painc 
 All (145 patients) 27 41 39 11 15 
 ICU treatmentd (76) 29 45 41 13 16 
 MOFe (53) 17 47 42 11 17 
 No MOF (92) 33 37 37 11 14 
 Operationf (43) 26 52 35 9   5g 
 No operation (102) 28 35 40 12 20 
 
aoral antidiabetic agents and/or insulin treatment. bnumbness in lower or upper limbs. cat least twice a week. 
dgeneral intensive care unit. eat least two organs’ failure in the Sequential Organ Failure Assessment score 
(SOFA) for any organ >2. fany kind of abdominal operation. goperation versus no operation p-value 0⋅02 
(from 2-tail Fischer test). Other differences non-significant. 
 
Of the 145 patients answering the questionnaire 113 had had alcohol-induced SAP. 30% of 
them did not use alcohol, 42%, used less than 280 g (190 g for women) absolute alcohol 
per week, and the remaining 28%, were problem drinkers (over 280 g pure alcohol per 
week for men and over 190 g for women), alcohol dependent or alcoholics (Sillanaukee 
1996). 
 
 
6.6 Discussion 
 
6.6.1 Hospital mortality among patients with SAP 
 
The overall mortality rate in the present study was 26%. The total mortality was similar 
between the two 5-year periods (1989-1993 and 1994-1998). In a series of 172 AP patients 
with sterile necrosis where the classification of severity was similar to the present one the 
overall mortality rate was 10% (13% in the operatively treated group and 6% in the 
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nonoperatively treated group) (Rau et al. 1995). In a series of 30 patients requiring ICU 
admission due to SAP, the mortality rate was 30% (Malcynsky et al. 1996).  
 
Improved survival of patients with necrotizing pancreatitis has been reported (Oleynikov et 
al. 1998, Kalfarentos et al. 1999). In the present study (table 4) mortality decreased in some 
subgroups of patients with SAP during the periods 1989-1993 and 1994-1998. The mortality 
of patients with SAP during the same five-year periods was with organ failure (42% and 
29%), early organ failure (62% and 46%), MOF (57% and 45%), and early MOF (74% and 
58%).  
 
The proportion of elderly SAP patients (age over 60 years) increased from 13% during the 
first 5-year period to 21% during the second period. Similarly the proportion of elderly 
patients among nonsurvivors almost doubled. This may explain the finding in this study that 
the total mortality did not change between the periods. 
 
Previous studies have recorded mortality rates between 40–80% for patients with infected 
necrosis (Renner et al. 1985, Allardyce 1987, Bradley 1989, Lumsden and Bradley 1990, 
Pederzoli et al. 1993, Ranson et al. 1997). According to this study the mortality rate during 
the second 5-year period for patients with infected peripancreatic necrosis was 46%, and 
56% if there was abdominal infection. However, only 28 % the patients who died (13 of 47) 
had infected peripancreatic necrosis and 57% of them (27 of 47) had abdominal infection. 
79% of the patients with SAP who underwent abdominal surgery had also an intra-
abdominal infection. 
 
6.6.2 Prognostic factors available on admission for hospital mortality in SAP 
 
Previous chronic medication is an indicator of patients’ overall health prior to the onset of 
the disease. This variable has not previously been reported to be a significant prognostic 
factor for fatal outcome in SAP. However, in study I multivariate logistic regression analysis 
showed that it was an independent prognostic factor for death in SAP. There were 
statistically significant associations between previous chronic medication and high age, high 
BMI and the need of pressor support and less significant association with etiology, which 
may explain the higher risk for fatal organ failure in this subset of patients. A history of 
chronic cardiovascular or anticoagulation medication is a new prognostic factor and it should 
alert clinicians for a potentially unfavorable outcome of patients with SAP (Study II). 
 
Advanced age has been identified as a negative prognostic indicator in AP (Ranson and 
Pasternack 1977, Blamey et al. 1984, Williamson 1984), although controversial results have 
been reported (Fan et al. 1988, Lankisch et al. 1996). In the present study, age was associated 
with BMI, etiology, history of previous medication and respiratory failure. However, 
advanced age proved to be an independent prognostic factor by univariate and multivariate 
survival analysis. 
 
BMI. The role of obesity has been emphasized as a prognostic factor in AP (Lankisch et al. 
1990, Porter and Banks 1991, Funnell et al. 1993). In a series of 320 patients with AP the 
mortality rate was not higher in obese patients, but obese patients had a higher risk for 
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developing local complications in the course of AP (Tsai 1998). The present study (Study I) 
identified BMI as a prognostic factor in SAP in univariate analysis but it was not an 
independent factor by multivariate logistic regression analysis. BMI was associated with 
several other prognostic variables, such as age and history of chronic medication, first 
episode of AP, development of renal and respiratory failure and need of pressor support. 
According to this study these multiple associations explain largely the unfavorable outcome 
of patients with a high BMI. 
 
Etiology. Several studies have shown different outcomes depending on the etiology of AP 
(Imrie 1974, Ranson et al. 1976, Frey 1981), although in a report of 190 patients, the cause 
of the AP was not associated with mortality (Uhl et al. 1996). This is keeping with this study 
results; neither univariate nor multivariate analysis identified etiology as an independent 
prognostic factor. However, the early identification of biliary AP remains of outmost 
importance, because this condition requires in some case adequate early endoscopic 
treatment. 
 
Type of admission. In a study with 279 patients with AP, the mortality rate was 2% among 
patients who were directly admitted to the study hospital and it was 10-fold higher among 
the patients referred from another hospital (De Beux et al. 1995). This is in accordance with 
findings in this study (Study I and II): the prognosis of patients transferred from other 
hospitals was poorer, even to the extent that in the study II in my first models constructed for 
the test set the referral admission was a significant prognostic variable. There was a strong 
association between admission and respiratory, renal and cardiovascular organ failure, and 
this indicates that the referred patients were clinically in a more severe condition, which may 
be related to suboptimal early treatment or more severe disease. The poorer prognosis of the 
referred patients explains the relatively high total mortality in the present study. I 
recommend emergency transfer of patients with SAP within the first 72 hours of admission 
to primary a hospital to a hospital with expertise in the treatment of SAP and this is 
especially important for those who have advanced age, a history of chronic cardiovascular or 
anticoagulation medication and organ failure. The same conclusion was drawn in a study on 
patients with alcohol-induced acute pancreatitis and incipient organ failure (Lankisch et al. 
1999). 
 
6.6.3 Organ dysfunction associated with SAP 
 
 Single and multiple organ failure is known to predict the outcome of SAP patients 
(Lumsden and Bradley 1990, Karimgani et al. 1992, De Beaux et al. 1995 and 1996, Uomo 
et al. 1996a, Tenner et al. 1997). Studies I-III add evidence that organ failure is indeed an 
important prognostic factor in SAP. Consequently, every effort to reduce the risk of organ 
system dysfunction improves the chance of survival. 
 
In studies I and II the need for mechanical ventilation or the need of vasoactive drugs in the 
early phase of SAP were identified as important prognostic factors. The most significant 
factor predictive of inpatient death early in SAP was the highest serum creatinine value 
within 60 to 72 hours of admission. This variable indicates frank renal failure, or incipient 
renal failure and thus every effort to protect the kidneys may improve the chances of 
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survival. The present study shows that organ failures in the early phase of SAP are 
independent prognostic factors, and the same conclusion was drawn in a study by Isenmann 
et al. (2001). In a recent study, early organ dysfunction in AP resolves and does not seem to 
have a significant impact on mortality. In contrast, worsening of organ dysfunction is 
associated with death (Buter et al. 2002).  
 
 
According to study III, the respiratory organ failure was more common than failure in the 
other organs. However, the mortality rate in the respiratory failure group was 43% which is 
lower than for the other organ failure groups. Hepatic system failure was associated with the 
highest mortality (83%). This is keeping with the findings of SOFA-group work (Vincent et 
al. 1996). In a study involving 267 patients with AP, the mortality rate among patients with 
acute renal failure was 81%, compared to 83% with cardiovascular failure and 72% with 
hematological failure (Tran et al. 1993b). In my study, mortality rates of patients with SAP 
and renal, cardiovascular and coagulation organ failure were 63%, 55%, and 56%, 
respectively. This difference in mortality can, in part, be caused by the different criteria for 
definition of organ failure. In my study, multiple logistic regression analysis showed that 
failure, only of the hepatic, renal, and cardiovascular systems was an independent inpatient 
mortality risk factor, whereas failure of the respiratory, coagulation, and neurologic systems 
was not. The prognostic value of neurologic failure was lower in my study than in the 
SOFA-group work (Vincent et al. 1998). In study I, respiratory failure was identified as an 
independent inpatient mortality risk factor. Dissimilar study populations may explain this 
difference. In study I, 50 % of patients needed mechanical ventilation, whereas in study III 
85% needed mechanical ventilation. 
 
The highest SOFA score for the individual organ systems was reached at different time 
points. The mean maximum SOFA score for the cardiovascular, hepatic, and coagulation 
systems was reached on day 3, for the respiratory and neurologic systems at the 14th day and 
for the renal system on day 21. These findings differ from those of the SOFA-group, who 
reported the shortest time to the mean maximum SOFA score for the respiratory system and 
the longest for the hepatic system (Vincent et al. 1998). 
 
 
6.6.4 Multiple organ dysfunction associated with SAP 
 
The present study demonstrated that organ dysfunction scores (MOD, LOD, and SOFA) 
predict well hospital mortality in patients with SAP. To my knowledge, this is the first study 
in which organ dysfunction scores have been used to predict hospital mortality in patients 
with SAP. SOFA scores had the highest discrimination values, but there was no statistically 
significant difference between organ dysfunction scores regarding AUCs. A good 
discrimination power is achieved when the daily maximum score of all organ dysfunction 
scores is recorded. The AUC values of the SOFA scores increased from the day 3 value to 
day 35 value. The AUCs of the organ dysfunction scores were better than APACHE II score 
in predicting of hospital mortality. 
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The mortality rate associated with a maximum daily SOFA score of more than 15 was lower 
than the one reported by the SOFA (Vincent et al. 1996). The present study (Figure 6) found 
a mortality of 50%-91% among SAP patients with failure of two organ system; this 
compares favorable with range of 48%-73% reported by the SOFA group (Vincent et al. 
1998). According to the present study, the range of mortality is wider than the one reported 
by the SOFA group (Vincent et al. 1996). The highest mortality rate (91%) in my study was 
recorded for the combination of hepatic and renal failure in SAP patient. Two studies have 
shown mortality rates between 80 and 86% for patients with AP and a combination of acute 
renal and hepatic failure (Tran et al. 1993b, Ljutic et al. 1996). In these two studies the 
criteria for hepatic failure differ slightly from those of the SOFA group. 
 
Throughout the duration of the hospital stay, mean daily SOFA scores were significantly 
higher for the nonsurvivors than for the survivors. According my study, the development of 
the daily SOFA score after day 14 seems to distinguish between SAP patients who will 
survive and who will not. 
 
6.6.5 Multifactorial models to predict mortality in patients with SAP 
 
The Ranson and Imrie scores have been developed for predicting the severity of AP but they 
have also been used for predicting hospital mortality (Ranson et al. 1974 and 1976, Corfield 
et al. 1985). Study II demonstrated that the Ranson and Imrie scores are not accurate 
predictors of a fatal outcome of patients with SAP. My study supports the conclusions of a 
meta-analysis regarding the predictive power of the Ranson score (De Bernardinis et al. 
1999). According to a recent study the Ranson score is as a valid predictor of mortality 
among SAP patients who are treated in a surgical ICU; the study excluded critically ill SAP 
patients who were treated in the medical ICU (Eachempati et al. 2002). 
 
The APACHE II and MODS systems have been used for predicting the outcome of severely 
ill patients. In the study II, these systems had a much higher accuracy than Ranson and Imrie 
scores, but a lower accuracy than my study new models. Both chosen models in my study 
(study II) resulted in higher AUC values (accuracy) than APACHE II and MODS, but the 
difference was not statistically significant. The main advantage of the novel LR4 model is 
that it is simple as compared with APACHE II and MODS. The LR4 model uses only four 
variable which are readily available and these four variables yield a higher accuracy than the 
14 variables and 96 alternatives in APACHE II. The four variables of the LR4 model are age, 
history of cardiovascular or anticoagulation medication, need for mechanical ventilation and 
highest serum creatinine value within 60-72 h from admission. 
  
 
ANN has been used to predict the duration of hospital stay of AP patient (Pofahl et al. 1998), 
but not for survival prediction. To my knowledge, this is the first study to use ANN to 
predict death in patients with SAP. It turned out that ANN did not offer any advantages over 
a logistic regression model. The ANN8 model with its eight variables had almost the same 
accuracy as the logistic model (LR4) with four variables. The four variables of LR4 were 
also tested in a neural network model (ANN4), but accuracy was not affected. This indicates 
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that there are only few nonlinearities or complex interactions between these four variables 
(Baxt 1994, Burke 1996).  
 
From these findings I conclude that the four variables in the LR4 model are independent 
predictors of hospital mortality early in SAP. 
 
Patients’ age and history of chronic medication were identified as factors to predict a fatal 
outcome (studies I and II). The organ dysfunction scores do not take into account these two 
confounding factors. Study III shows that in patients >60 yrs old, a SOFA score over 10 
indicates an extremely poor prognosis (mortality100 %). In that study, age was not an 
independent risk factor for death by in multiple regression analysis. Perhaps the multiple 
regression model used in study III as well as the small number of elderly patients treated in 
the general ICU underestimated the prognostic value of age. All 12 patients with a history of 
chronic cardiovascular medication and a SOFA score over 15 died. Early renal dysfunction 
in patients with a history of cardiovascular medication is also a sign of a poor prognosis. 20 
patients had early renal dysfunction (SOFA scores 1-4) and 14 of them had SOFA scores of 
2-4 on the day 3. The mortality rates in these two groups were 85% and 100%, respectively. 
This study shows that renal failure and a history of chronic cardiovascular medication are 
independently associated with a fatal outcome in this patient population. Apparently these 
patients have deficient physiological reserve for surviving. 
 
In 1973, Tilney suggested that, in patients with a ruptured abdominal aneurysm, the 
superimposition of pre-existing chronic cardiovascular disease on the mechanical and 
metabolic consequences of the surgical procedure leads to a high mortality. In patients with a 
history of cardiovascular medication, cytokines and inflammatory mediators in the early 
phase of SAP may initiate a vicious cycle and leads inevitably to death. Two studies have 
suggested that supranormal hemodynamic performance is needed by critically ill patients for 
survival from shock-related organ failures (Bishops et al. 1993, Shoemaker et al. 1993), and 
in patients with advanced age and cardiovascular disease, these values may be difficult to 
achieve. These findings may explain the poor outcome in these subgroups, because SAP can 
cause shock, which demands of a patient the ability to achieve these supranormal values.  
 
 
6.6.6 Long-term health-related quality of life in survivors after SAP 
 
The findings in study IV show that patients with long-term survival following SAP have a 
good quality of life, which seems to be comparable to that of the general population, as 
assessed with the Rand 36-item Health Survey. Although the difference in the general health 
domain was statistically significant, the Z score was below 2 and the differences between 
means was <10, and this indicates that the difference was not clinically significant (Pettilä et 
al. 2000).  
 
A study by Pettilä et al. (2000) demonstrated impairment in several domains of HRQL of 
ICU patients 1 year after discharge. Two studies used the 36-item short-form general health 
survey and found no statistically significant difference in HRQL between 22 SAP patients 
who were operated on and 21 others who had been treated in ICU (Broome et al. 1996, Soran 
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et al. 2000). The present study revealed no clinically significant difference in the HRQL 
when subgroups of patients with MOF or undergoing ICU or surgical treatment were 
analyzed. 
 
Multiple regression analysis showed that only the employment status before SAP and the age 
during the study period were independently associated with some HRQL domains. Follow-
up time, etiology of SAP, gender, ICU treatment, duration of ICU stay, MOF and need for 
abdominal operation did not affect adversely the HRQL among long-term survivors of SAP. 
 
6.6.7 Long-term outcome in survivors of SAP 
 
This study found that 87% of the patients who were working the year before the onset of 
SAP returned to work, which confirms the results of a previous Finnish study showing that 
77% of ICU treated SAP patients returned to work (Doepel et al. 1993).  
 
The overall incidence of diabetes in my study was 47%. Previous studies have reported an 
incidence of 83-100% after distal resection of the pancreas required for treatment of SAP 
(Nordback et al. 1985c, Schröder et al. 1990, Doepel et al. 1993). Büchler et al. (1987) found 
that one-half of the patients developed subclinical or overt diabetes after necrosectomy or 
closed lavation. The incidence of diabetes in this study among eight patients with pancreatic 
resection was 100% and among the 31 who underwent digital necrosectomy 52%. This study 
adds evidence that pancreas-preserving necrosectomy is associated with a lower risk of 
diabetes. However, the follow-up period in my study may have been too short to assess the 
impact of diabetes on HRQL, if any.  
 
The mortality rate in this study was 25%. This figure is comparable to the one reported from 
other tertiary referral center (De Beaux et al. 1995). According this study (study IV), an 
additional 10% of patients died within a few years, mostly from alcoholism and pancreas-
related diseases, mainly diabetes. This has not been published previously. In the present 
study, 78% of the patients had alcohol-induced pancreatitis, and it was encouraging that 30% 
of them became totally abstinent and that 42% reduced their alcohol intake to a reasonable 
level. 
 
6.6.8 Study limitations 
 
Several limitations of this study should be addressed. Firstly, data collection was 
retrospective in study III and partly retrospective in studies I and II. However, the proportion 
of missing values in study III {most frequently serum bilirubin [21 missing values out of 678 
(3.1%)]} was fairly small [total missing values was 52 out of 8249 (0.6%)]. Statistically, the 
missing data did not have any notable affect on the results. Secondly, the scores compared in 
study III were not published at the time of the beginning of the study period, and MOD 
scores are based on efficient registration of routine laboratory values and vasoactive 
medication. Thirdly, because I collected data over only 7 days during a period of 35 days in 
study III, I may have missed some valuable information on the maximal values. Fourthly, 
because this study was partly retrospective, I was not able to estimate the prognostic value 
with regard to survive of serum calcium, the amount of pancreatic necrosis and the value of 
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early prophylactic antibiotic in the treatment of SAP. Fifthly, I was not able to include the 
variable infected pancreatic necrosis in the analyses of mortality (study I). Sixthly, the new 
prognostic models (study II) require 72 h of follow-up data as of admission and this time 
seems to be too long to allow starting some (e.g., anticytokine) therapies to treat AP and 
SAP. However, the models in this study were developed primarily for predicting hospital 
mortality and not to classify the severity of AP. 
 
Seventhly, I had no baseline measurement for assessment of QOL with the Rand 36 tool 
(study IV); it is most difficult to obtain baseline data in all patients with SAP. Eightly, the 
Rand 36 survey is not validated nor has its reliability been tested in SAP patients. 
Furthermore, the assessment of the level of clinical relevance for any difference in QOL 
values is arbitrary and may well be criticized. Very few QOL studies have succeeded in 
meeting strict methodological criteria (Heyland et al. 1998). However, Rand 36 has been 
shown to be a valid and reliable measure of HQOL in critical ill patients with sepsis 
(Heyland et al. 2000).  
 
6.6.9 Clinical implications 
 
It is, in my opinion, of utmost clinical importance to increase the accuracy of prognostic 
systems, especially those related to hospital mortality. Early identification of high-risk 
patients with SAP may have several clinical consequences. These patients should be referred 
to a specialized unit swiftly. Clearly, there is a need to improve the treatment of this group 
since their outcome is not good. New types of immunosupportive and anticytokine therapies 
carry promise of improved treatment. The optimal target group of these therapies might be 
patients with a predicted poor prognosis. The novel LR4 model is feasible for enrolling 
patients with SAP in prospective trials focusing on hospital. The prognostic score generated 
by the LR4 model has been validated only in a relatively small population and mainly 
alcohol-induced SAP. However, my studies and earlier studis have not established the 
etiology of SAP as a significant prognostic factor for hospital mortality (Uhl et al. 1996). 
The model requires further validation before it may be recommended for use in the clinics. 
Also, an evaluation of how close the predictions are to the actual death rate (calibration) still 
needs to be corroborated. 
 
The importance of study III lies in that it validates some organ dysfunction scores (MOD, 
LOD, and SOFA) in the target population of ICU treated SAP patients (Miskovitz 2002). 
According to this study, organ dysfunction scores are simple and useful for assessing MOD 
and for predicting a fatal outcome of patients with SAP. I recommed the routine use of one 
of them in clinical work. 
  
Although the present study found that some subgroups have a very poor prognosis, it is 
underpowered to allow any definitive conclusions about the power to predict a poor outcome 
(as to support end-of-life decisions) in clinical practice. Large prospective studies are needed 
to confirm these findings. 
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This study (study IV) may have implications at the microeconomic level, where it can be 
used as a tool to encourage ICUs in hospitals to do follow-up surveys and assess the long-
term efficiency of the treatment provided at the ICUs.  
 
Whether the present results can be used to justify the management of SAP patients in 
general, is in my view, controversial. However, according to the present study it seems to be 
worthwhile to treat actively patients with SAP, although the cost of treatment is high. The 
long-term health-related quality of life of patients surviving a bout of SAP is comparable to 
that of the general population, and thus maximal treatment of these patients seems to be 
justified. 
 
 
6.6.10 Future directions 
 
Despite numerous studies AP is still a poorly understood disease. There is a large number of 
studies using univariate analysis to identify prognostic factors in AP. However, the outcome 
in SAP depends on multiple intermingled variables making the prediction unreliable, even by 
multivariate analysis. 
 
To achieve a clinically acceptable accuracy for the predicting the outcome of patients with 
SAP, better prediction models than those currently available are required. One solution could 
be to identify separate prognostic factors as markers of severity of disease and of fatal 
outcome. 
 
This study shows that 79% of patients who died had organ failure within 72 hours of 
admission and 67% of the patients who died had early MOF (within 72 hours of admisson). 
In study by Johnson et al. (2001) 44% of patients with SAP had organ failure on admission 
and 97% of the patients who died had organ failure within the first week of admission. To 
decrease hospital mortality in patients with SAP, it is important to predict early organ 
dysfunction/failure to allow immediate transfer of these patients to specialized units. High-
risk SAP patients should be identified by a single or multifactorial testing on admission or 
during the early hours of an attack of AP to predict single or multiple organ failure. This is 
also needed for identification of patients that should be invited to participate in future trials. 
 
Althoug there are no drugs, as yet, to prevent or cure MOF, the development of a new type 
of immunosupportive and anticytokine therapies is ongoing. Supraphysiological doses of 
hydrocortisone intravenously early (8-24h from start) during the course of septic shock (50-
100 mg 3-4 times per day during 5 to 7 days) have been shown to reduce mortality (Bollaert 
et al. 1998, Briegel et al. 1999). This treatment should be considered also for patients with 
SAP who need vasoactive pressor support for a longer time (48 hours). Similarly, the use of 
physiological anticoagulants antitrombin III and activated protein C reduces mortality in 
patients with sepsis (Eisele et al. 1998, Bernard 2001) and thus this treatment should be also 
considered for SAP patients.  
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Morbidity and mortality among critically ill patients is reduced by intesive insulin therapy 
targeted at maintaining the blood glucose concentration between 4 to 6 mmol/L (Van den 
Berghe et al. 2001). This therapy should also be considered for patients with SAP. 
 
Increased intra-abdominal pressure (IAP), which may lead to the abdominal compartment 
syndrome, is a known complication of SAP (Gecelter et al. 2002). Some patients may be 
treated by abdominal decompressive laparotomy (Gecelter et al. 2002), but the value of a 
decompressing laparotomy will have to be studied in a randomized controlled trial before 
any recommendations can be made (Sugrue 2002, Z’graggen and Gloor 2002). 
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6.7 Conclusions 
 
 
 
1. The following independent prognostic factors for hospital mortality in patients with 
severe acute pancreatitis (SAP) were identified: advanced age, need of dialysis, need of 
mechanical ventilator support, need of pressor support and previous chronic 
medication (a marker of the overall health of the patient before the onset of SAP). 
 
 
 
2. The novel logistic regression predicting model with four easily available variables has 
a higher accuracy as compared with 14 variables (12 physiological variables and points 
for age and chronic health) and 96 alternatives in APACHE II. According to our study 
Ranson and Imrie scores are inaccurate indicators of the mortality in SAP. Organ 
failures in the early phase of SAP are the best predictors of mortality. Age and 
comorbid diseases must be taken into account when predicting the survival of patients 
with SAP. The new four-variable predicting model identifies patients with a high risk 
of death early in SAP. 
 
 
 
3. The SOFA, MOD, and LOD multiple organ dysfunction scores are effective predictors 
of hospital mortality among patients with SAP treated in a general ICU. The SOFA 
scores had the highest discrimination values, although the differences were not 
statistically significant. The maximum daily multiple organ dysfunction scores are 
simple and useful for assessing multiple organ dysfunctions and predicting hospital 
mortality rates in patients with SAP. Hepatic, renal, and cardiovascular failure and a 
history of chronic cardiovascular medication were independent risk factors for hospital 
mortality in this high-risk patients group. 
 
 
 
4. A significant proportion of patients with mainly alcohol-induced SAP surviving initial 
hospitalization die within a few years from alcoholism and pancreas-related disease. 
HRQL among the survivors is comparable to that in the general population, and the 
majority returns to work and reduce their alcohol consumption markedly. 
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